{"content":"<li class=\"n-box-item date-title\" data-end=\"1507175999\" data-start=\"1507089600\" data-txt=\"Monday, December 23, 2019\">Wednesday, October  4, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3299443\" data-ts=\"1507155920\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LVLT\" target=\"_blank\">LVLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299443-ppbiplus-4_7-on-move-to-s-and-p-smallcap-600-nclh-to-s-and-p-500\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PPBI +4.7% on move to S&amp;P SmallCap 600; NCLH to S&amp;P 500</a></h4><ul>   <li>Norwegian Cruise Line Holdings (<a href=\"http://seekingalpha.com/symbol/NCLH\" target=\"_blank\">NCLH</a> <font color='green'>+2.3%</font>) is <a href=\"https://www.spice-indices.com/idpfiles/spice-assets/resources/public/documents/593950_cruise5century6pacific.pdf?force_download=true\" target=\"_blank\">joining the S&amp;P 500</a>, effective before the open on Friday, Oct. 13.</li>    <li>The company is replacing Level 3 Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/LVLT' title='Level 3 Communications, Inc.'>LVLT</a>), set to be acquired by existing S&amp;P 500 constituent CenturyLink around that time.</li>    <li>Meanwhile, Pacific Premier Bancorp (<a href=\"http://seekingalpha.com/symbol/PPBI\" target=\"_blank\">PPBI</a> <font color='red'>-1.8%</font>) is <font color='green'>up 4.7%</font> after hours as it heads into the SmallCap 600 before the open Thursday, Oct. 12.</li><li>It's replacing Parkway (NYSE:<a href='https://seekingalpha.com/symbol/PKY' title='Parkway Properties Inc.'>PKY</a>), set to be acquired by the Canada Pension Investment Board.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299443\" data-linked=\"PPBI +4.7% on move to S&amp;P SmallCap 600; NCLH to S&amp;P 500\" data-tweet=\"$LVLT $LVLT $PKY - PPBI +4.7% on move to S&amp;P SmallCap 600; NCLH to S&amp;P 500 https://seekingalpha.com/news/3299443-ppbiplus-4_7-on-move-to-s-and-p-smallcap-600-nclh-to-s-and-p-500?source=tweet\" data-url=\"https://seekingalpha.com/news/3299443-ppbiplus-4_7-on-move-to-s-and-p-smallcap-600-nclh-to-s-and-p-500\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299439\" data-ts=\"1507154161\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTDR\" target=\"_blank\">MTDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299439-matador-resources-to-launch-8m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Matador Resources to launch 8M-share offering</a></h4><ul>     <li>Matador Resources (NYSE:<a href='https://seekingalpha.com/symbol/MTDR' title='Matador Resources'>MTDR</a>) <font color='red'>-1.6%</font> after-hours after commencing a <a href=\"https://seekingalpha.com/pr/16960023-matador-resources-company-announces-commencement-public-offering-common-stock\" target=\"_blank\">public offering</a> of 8M common shares.</li>     <li>MTDR says it plans to use the proceeds to fund the purchase of 9,800 gross acres in the Delaware Basin in and around its existing acreage positions, to fund capex for various midstream       initiatives in the Delaware Basin that are either in progress or expected to begin by the end of Q1 2018, and for general corporate purposes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299439\" data-linked=\"Matador Resources to launch 8M-share offering\" data-tweet=\"$MTDR - Matador Resources to launch 8M-share offering https://seekingalpha.com/news/3299439-matador-resources-to-launch-8m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3299439-matador-resources-to-launch-8m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299436\" data-ts=\"1507152927\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299436-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/MOBL' title='MobileIron, Inc.'>MOBL</a> <font color='green'>+9.3%</font>. <a href='https://seekingalpha.com/symbol/ACAD' title='ACADIA Pharmaceuticals Inc.'>ACAD</a> <font color='green'>+5.4%</font>. <a href='https://seekingalpha.com/symbol/ZUMZ' title='Zumiez Inc.'>ZUMZ</a> <font color='green'>+4.5%</font>. <a href='https://seekingalpha.com/symbol/SEAS' title='SeaWorld Entertainment Inc.'>SEAS</a> <font color='green'>+3.8%</font>. <a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a> <font color='green'>+2.5%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a> <font color='red'>-8.3%</font>. <a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a> <font color='red'>-8.1%</font>. <a href='https://seekingalpha.com/symbol/AYI' title='Acuity Brands, Inc. &#40;Holding Company&#41;'>AYI</a> <font color='red'>-3.9%</font>. <a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a> <font color='red'>-2.3%</font>. <a href='https://seekingalpha.com/symbol/FGEN' title='FibroGen'>FGEN</a> <font color='red'>-1.8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299436\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$MOBL $ACAD $ZUMZ - After Hours Gainers / Losers https://seekingalpha.com/news/3299436-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3299436-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299435\" data-ts=\"1507152018\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONVO\" target=\"_blank\">ONVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299435-organovo-to-cut-13-of-workforce-announces-preliminary-revenues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Organovo to cut 13% of workforce, announces preliminary revenues</a></h4><ul>   <li>Organovo (<a href=\"http://seekingalpha.com/symbol/ONVO\" target=\"_blank\">ONVO</a> <font color='red'>-7.7%</font>) is <font color='green'>up 1.5%</font> after hours following the release of preliminary Q2 revenues and word that the company will <a href=\"https://seekingalpha.com/pr/16960142-organovo-announces-preliminary-fiscal-second-quarter-total-revenue-company-restructures\" target=\"_blank\">cut 13% of its workforce</a> in a restructuring.</li>    <li>That amounts to about 15 positions, with actions expected to be completed by year-end. Organovo says it will \"consolidate overlapping positions and streamline the Company&rsquo;s management structure.\"</li>    <li>The company will take a charge of about $0.9M in Q3 tied to severance and benefits costs; it believes the job cuts will cut operating costs by $1.3M in fiscal 2018 (improving an expected negative EBITDA) and $2.7M in fiscal 2019.</li>    <li>It says preliminary Q2 revenue will be $1.3M-$1.4M (made up largely of product and service revenue), below consensus for $1.46M. At the midpoint, that's a 2% Y/Y decline, but up 36% sequentially.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299435\" data-linked=\"Organovo to cut 13% of workforce, announces preliminary revenues\" data-tweet=\"$ONVO - Organovo to cut 13% of workforce, announces preliminary revenues https://seekingalpha.com/news/3299435-organovo-to-cut-13-of-workforce-announces-preliminary-revenues?source=tweet\" data-url=\"https://seekingalpha.com/news/3299435-organovo-to-cut-13-of-workforce-announces-preliminary-revenues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299432\" data-ts=\"1507151102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSAT\" target=\"_blank\">GSAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299432-globalstarminus-3_7-on-plans-for-125m-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Globalstar -3.7% on plans for $125M equity offering</a></h4><ul>   <li>Shares in Globalstar (<a href=\"http://seekingalpha.com/symbol/GSAT\" target=\"_blank\">GSAT</a> <font color='green'>+3.3%</font>) have <font color='red'>dipped 3.7%</font> on heavy after-hours volume after word from Bloomberg that the company's <a href=\"https://seekingalpha.com/filing/3719847\" target=\"_blank\">offering $125M in shares</a>.</li>    <li>The company will use 80% of the proceeds for deposits into a restricted account, to pay facility agreement obligations.</li>    <li>The offering will start trading Friday, Bloomberg says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299432\" data-linked=\"Globalstar -3.7% on plans for $125M equity offering\" data-tweet=\"$GSAT - Globalstar -3.7% on plans for $125M equity offering https://seekingalpha.com/news/3299432-globalstarminus-3_7-on-plans-for-125m-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3299432-globalstarminus-3_7-on-plans-for-125m-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299413\" data-ts=\"1507149306\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACAD\" target=\"_blank\">ACAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299413-acadia-launches-late-stage-study-of-nuplazid-in-dementia-related-psychosis-shares-ahead-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ACADIA launches late-stage study of Nuplazid in dementia-related psychosis; shares ahead 4% after hours</a></h4><ul><li>ACADIA Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACAD' title='ACADIA Pharmaceuticals Inc.'>ACAD</a>) is up&nbsp;<font color='green'>4%</font>&nbsp;after hours on robust volume on the heels of its <a href=\"https://seekingalpha.com/pr/16960009-acadia-pharmaceuticals-initiates-phase-iii-study-pimavanserin-dementia-related-psychosis\" target=\"_blank\">announcement </a>of the start of a Phase 3 clinical trial, HARMONY, assessing NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis, a Breakthrough Therapy-tagged indication.</li><li>HARMONY will have a 12-week open-label stabilization period during which participants will receive a daily dose of 34 mg (20 mg if clinically justified) of pimavanserin. Afterward, those who meet prespecified criteria for treatment response will be randomized to continue to receive daily pimavanserin (34 mg or 20 mg) or placebo for up to 26 weeks. The primary endpoint is time to relapse in the double-blind period.</li><li>NUPLAZID is currently approved in the U.S. to treat hallucinations and delusions associated with Parkinson's disease psychosis.</li><li>The company will host a conference call today at 5:00 pm ET to discuss the study.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3231684-acadia-giving-gains-investors-realize-successful-mid-stage-pimavanserin-failed-achieve\" target=\"_blank\">Acadia giving up gains as investors realize the \"successful\" mid-stage of pimavanserin failed to achieve the primary endpoint</a> (Dec. 20, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299413\" data-linked=\"ACADIA launches late-stage study of Nuplazid in dementia-related psychosis; shares ahead 4% after hours\" data-tweet=\"$ACAD - ACADIA launches late-stage study of Nuplazid in dementia-related psychosis; shares ahead 4% after hours https://seekingalpha.com/news/3299413-acadia-launches-late-stage-study-of-nuplazid-in-dementia-related-psychosis-shares-ahead-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3299413-acadia-launches-late-stage-study-of-nuplazid-in-dementia-related-psychosis-shares-ahead-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299412\" data-ts=\"1507149301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSGN\" target=\"_blank\">MSGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299412-charter-last-distributor-to-offer-msg-networks-streaming-service\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Charter last distributor to offer MSG Networks streaming service</a></h4><ul>   <li>MSG Networks (<a href=\"http://seekingalpha.com/symbol/MSGN\" target=\"_blank\">MSGN</a> <font color='green'>+2.1%</font>) and Charter (<a href=\"http://seekingalpha.com/symbol/CHTR\" target=\"_blank\">CHTR</a> <font color='green'>+0.4%</font>) have a deal to make the network's \"MSG GO\" streaming/VOD platform <a href=\"https://seekingalpha.com/pr/16959524-msg-networks-spectrum-partner-make-msg-go-available-spectrum-subscribers\" target=\"_blank\">available to Charter's pay TV subscribers</a>.</li>    <li>That means MSG GO is available from all of MSG Networks' major distributors.</li>    <li>The move came in time to offer live game coverage of key MSG-audience teams as the NBA and NHL seasons begin, including the New York Knicks, New York Rangers, New Jersey Devils, New York Islanders, Buffalo Sabres, New York Liberty and New York Red Bulls.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299412\" data-linked=\"Charter last distributor to offer MSG Networks streaming service\" data-tweet=\"$MSGN $MSGN $CHTR - Charter last distributor to offer MSG Networks streaming service https://seekingalpha.com/news/3299412-charter-last-distributor-to-offer-msg-networks-streaming-service?source=tweet\" data-url=\"https://seekingalpha.com/news/3299412-charter-last-distributor-to-offer-msg-networks-streaming-service\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299406\" data-ts=\"1507148977\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEAS\" target=\"_blank\">SEAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299406-seaworld-jumps-7-on-report-of-buyer-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seaworld jumps 7% on report of buyer interest</a></h4><ul><li>According to Bloomberg, Merlin Entertainment and others have approached SeaWorld (NYSE:<a href='https://seekingalpha.com/symbol/SEAS' title='SeaWorld Entertainment Inc.'>SEAS</a>) about a deal for at least part of the company.</li><li>Shares&nbsp;<font color='green'>+7.3%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3299406\" data-linked=\"Seaworld jumps 7% on report of buyer interest\" data-tweet=\"$SEAS - Seaworld jumps 7% on report of buyer interest https://seekingalpha.com/news/3299406-seaworld-jumps-7-on-report-of-buyer-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3299406-seaworld-jumps-7-on-report-of-buyer-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299402\" data-ts=\"1507148424\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LGND\" target=\"_blank\">LGND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299402-ligand-pharma-to-buy-crystal-bioscience-for-up-to-35_5m-shares-up-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ligand Pharma to buy Crystal Bioscience for up to $35.5M; shares up 1% after hours</a></h4><ul><li>Ligand Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/LGND' title='Ligand Pharmaceuticals Incorporated'>LGND</a>) inks an <a href=\"https://seekingalpha.com/pr/16960005-ligand-acquire-crystal-bioscience-leader-chicken-derived-fully-human-antibody-generation-25\" target=\"_blank\">agreement </a>to acquire antibody discovery outfit <a href=\"http://www.crystalbioscience.com/\" target=\"_blank\">Crystal Bioscience</a> for $25M in cash and up to $10.5M in success-based milestones. Crystal will also share in revenues from existing licensees for a defined period.</li><li>Crystal's core technology, HuMab (branded as OmniChicken by Ligand), is a chicken-based antibody platform used to generate human antibodies. Its value proposition is the ability to generate novel antibodies against targets that are not immunogenic in mammals, thereby extending Ligand's position in transgenic antibody discovery.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299402\" data-linked=\"Ligand Pharma to buy Crystal Bioscience for up to $35.5M; shares up 1% after hours\" data-tweet=\"$LGND - Ligand Pharma to buy Crystal Bioscience for up to $35.5M; shares up 1% after hours https://seekingalpha.com/news/3299402-ligand-pharma-to-buy-crystal-bioscience-for-up-to-35_5m-shares-up-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3299402-ligand-pharma-to-buy-crystal-bioscience-for-up-to-35_5m-shares-up-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299401\" data-ts=\"1507148304\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BWLD\" target=\"_blank\">BWLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299401-buffalo-wild-wings-back-below-100\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buffalo Wild Wings back below $100</a></h4><ul><li>Buffalo Wild Wings (<a href='https://seekingalpha.com/symbol/BWLD' title='Buffalo Wild Wings, Inc.'>BWLD</a>) ended the day&nbsp;<font color='red'>down 4.81%</font>&nbsp;after Dougherty &amp; Co. lowered estimates on the restaurant operator.</li><li>Analyst Jeremy Hablin cited higher chicken wing costs and low NFL ratings as two points of concern.</li><li>He is also not a believer in the franchising plan of BWLD&nbsp;management.</li><li>BWLD closed below $100 for the first time in four weeks.</li><li>Sources: CNBC and Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3299401\" data-linked=\"Buffalo Wild Wings back below $100\" data-tweet=\"$BWLD - Buffalo Wild Wings back below $100 https://seekingalpha.com/news/3299401-buffalo-wild-wings-back-below-100?source=tweet\" data-url=\"https://seekingalpha.com/news/3299401-buffalo-wild-wings-back-below-100\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299397\" data-ts=\"1507147746\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAFD\" target=\"_blank\">CAFD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299397-8point3-energy-partners-reports-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">8point3 Energy Partners reports Q3 results</a></h4><ul><li>8point3 Energy Partners (NASDAQ:<a href='https://seekingalpha.com/symbol/CAFD' title='8point3 Energy Partners LP'>CAFD</a>): Q3 EPS of $0.27</li><li>Revenue of $27.74M (+6.2% Y/Y)</li><li>Shares <font color='green'>+1.4%</font>.</li><li><a href='https://seekingalpha.com/pr/16960004-8point3-energy-partners-reports-third-quarter-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3299397\" data-linked=\"8point3 Energy Partners reports Q3 results\" data-tweet=\"$CAFD - 8point3 Energy Partners reports Q3 results https://seekingalpha.com/news/3299397-8point3-energy-partners-reports-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3299397-8point3-energy-partners-reports-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299396\" data-ts=\"1507147651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMGN\" target=\"_blank\">IMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299396-immunogen-readies-13m-share-stock-offering-shares-down-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ImmunoGen readies 13M-share stock offering; shares down 3% after hours</a></h4><ul><li>ImmunoGen (NASDAQ:<a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a>) slips&nbsp;<font color='red'>3%</font>&nbsp;after hours in response to its<a href=\"https://seekingalpha.com/pr/16959991-immunogen-announces-proposed-public-offering-common-stock\" target=\"_blank\"> planned public offering</a> of 13M shares of common stock. Price and terms have yet to be announced.</li><li>Net proceeds will fund R&amp;D, business activities and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299396\" data-linked=\"ImmunoGen readies 13M-share stock offering; shares down 3% after hours\" data-tweet=\"$IMGN - ImmunoGen readies 13M-share stock offering; shares down 3% after hours https://seekingalpha.com/news/3299396-immunogen-readies-13m-share-stock-offering-shares-down-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3299396-immunogen-readies-13m-share-stock-offering-shares-down-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299395\" data-ts=\"1507147649\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPY\" target=\"_blank\">BPY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299395-late-rise-for-brookfield-property-said-to-be-exploring-options\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Late rise for Brookfield Property, said to be exploring options</a></h4><ul><li>According to Reuters, the company is mulling options for its office holdings in the Northeast U.S. The assets under consideration could be valued at up to $10B.</li><li><a href='https://seekingalpha.com/symbol/BPY' title='Brookfield Property Partners L.P.'>BPY</a>&nbsp;<font color='green'>+2.45%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3299395\" data-linked=\"Late rise for Brookfield Property, said to be exploring options\" data-tweet=\"$BPY - Late rise for Brookfield Property, said to be exploring options https://seekingalpha.com/news/3299395-late-rise-for-brookfield-property-said-to-be-exploring-options?source=tweet\" data-url=\"https://seekingalpha.com/news/3299395-late-rise-for-brookfield-property-said-to-be-exploring-options\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299392\" data-ts=\"1507147131\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PED\" target=\"_blank\">PED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299392-pedevcominus-30-on-termination-of-equity-funding-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pedevco -30% on termination of equity funding deal</a></h4><ul>     <li>Pacific Energy Development (<a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a> <font color='red'>-30.2%</font>) plunges after announcing the <a href=\"https://www.streetinsider.com/Corporate+News/Pacific+Energy+Development+%28PED%29+Reports+Termination+of+Pending+Equity+Funding+Transaction/13361288.html\" target=\"_blank\">termination</a> of its pending equity funding transaction, and says it seeking a new equity funding source.</li>     <li>PED says the funding previously announced on June 22 was terminated due to a failure to agree on extending the Sept. 30 outside closing date to accommodate the  time needed for the deal's approval by the Committee on Foreign Investment in the U.S.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299392\" data-linked=\"Pedevco -30% on termination of equity funding deal\" data-tweet=\"$PED - Pedevco -30% on termination of equity funding deal https://seekingalpha.com/news/3299392-pedevcominus-30-on-termination-of-equity-funding-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3299392-pedevcominus-30-on-termination-of-equity-funding-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299385\" data-ts=\"1507146245\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPST\" target=\"_blank\">CPST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299385-capstone-turbineplus-21-following-oppenheimer-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capstone Turbine +21% following Oppenheimer upgrade</a></h4><ul>     <li>Capstone Turbine (<a href='https://seekingalpha.com/symbol/CPST' title='Capstone Turbine Corporation'>CPST</a> <font color='green'>+20.6%</font>) soars after Oppenheimer <a href=\"http://247wallst.com/energy-business/2017/10/04/why-fuelcell-could-double-and-capstone-turbine-could-rise-200/\" target=\"_blank\">upgrades</a> shares to Outperform from Perform with a $2 price target, believing CPST's sales and gross margin have bottomed out at a time the company is actively and effectively managing its cash.</li>     <li>Oppenheimer says CPST has effectively rationalized its overhead while working through a difficult demand cycle; at the same time, the firm says CPST trades at an enterprise value of $24M including $10M in net cash, vs. nearly $100M in annual sales.</li>     <li>The firm anticipates order activity picking up and estimates CPST will reach EBITDA breakeven in FY 2019 as order activity translates into sales growth.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299385\" data-linked=\"Capstone Turbine +21% following Oppenheimer upgrade\" data-tweet=\"$CPST - Capstone Turbine +21% following Oppenheimer upgrade https://seekingalpha.com/news/3299385-capstone-turbineplus-21-following-oppenheimer-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3299385-capstone-turbineplus-21-following-oppenheimer-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299379\" data-ts=\"1507144734\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XON\" target=\"_blank\">XON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299379-epa-now-regulator-for-oxitecs-engineered-mosquitoes-parent-intrexon-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EPA now the regulator for Oxitec&#39;s engineered mosquitoes; parent Intrexon up 1%</a></h4><ul><li>The FDA's Center for Veterinary Medicine <a href=\"http://www.prnewswire.com/news-releases/transfer-of-regulatory-jurisdiction-for-oxitecs-self-limiting-friendly-aedes-in-the-united-states-649442113.html\" target=\"_blank\">issues new guidanc</a>e that transfers regulatory jurisdiction for Intrexon (<a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a> <font color='green'>+1.3%</font>) unit Oxitec's Friendly Aedes mosquito (OX513A) to the Environmental Protection Agency &#40;EPA&#41; since it is considered a pesticide product.</li><li>FDA-CVM guidance clarifies \"<i>that mosquito-related products intended to function as pesticides by  preventing, destroying, repelling, or mitigating mosquitoes for  population control purposes, and that are not intended to cure,  mitigate, treat or prevent a disease (including by an intent to reduce  the level, replication or transmissibility of a pathogen in mosquitoes),  are not </i> <i>\"</i><i>drugs</i><i>\"</i><i> under the Federal Food, Drug, &amp; Cosmetic Ac</i><i>t, </i> <i>and will be regulated by the EPA under the Federal Insecticide, Fungicide, and Rodenticide Act</i><i>&hellip;</i><i>With the issuance of final guidance #236, Oxitec Ltd</i><i>'</i><i>s genetically engineered mosquito, with its proposed claim to control the population of wild-type </i> <i>A</i><i>edes aegypti mosquitoes, now falls under EPA</i><i>'</i><i>s regulatory authority and all related regulatory questions should be directed to the EPA.</i>\"</li><li>Oxitec says once EPA registration is completed it will work with state and local authorities on the coordinated release of OX513A.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299379\" data-linked=\"EPA now the regulator for Oxitec&#39;s engineered mosquitoes; parent Intrexon up 1%\" data-tweet=\"$XON - EPA now the regulator for Oxitec&#39;s engineered mosquitoes; parent Intrexon up 1% https://seekingalpha.com/news/3299379-epa-now-regulator-for-oxitecs-engineered-mosquitoes-parent-intrexon-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3299379-epa-now-regulator-for-oxitecs-engineered-mosquitoes-parent-intrexon-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299378\" data-ts=\"1507143849\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CI\" target=\"_blank\">CI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299378-collegium-inks-deal-cigna-for-oxycodone-equivalent-share-rise-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Collegium inks deal with Cigna for Oxycodone equivalent; share rise 1%</a></h4><ul><li>Part of a plan to cut opioid usage among its customers by 25% by 2019, Cigna (NYSE:<a href='https://seekingalpha.com/symbol/CI' title='Cigna Corporation'>CI</a>) will no longer cover OxyContin as a preferred option on the insurer's group commercial drug list, effective Jan. 1.</li><li>The company has signed a value-based contract with Collegium Pharma (<a href='https://seekingalpha.com/symbol/COLL' title='Collegium Pharmaceutical'>COLL</a> <font color='green'>+0.9%</font>) for the drug Xtampza ER, an oxycodone equivalent with abuse deterrent properties.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16959878-b-cigna-b-committed-reducing-opioid-use-removing-oxycontin-group-commercial-drug-lists-1-1-18\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3299378\" data-linked=\"Collegium inks deal with Cigna for Oxycodone equivalent; share rise 1%\" data-tweet=\"$CI $CI $COLL - Collegium inks deal with Cigna for Oxycodone equivalent; share rise 1% https://seekingalpha.com/news/3299378-collegium-inks-deal-cigna-for-oxycodone-equivalent-share-rise-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3299378-collegium-inks-deal-cigna-for-oxycodone-equivalent-share-rise-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299375\" data-ts=\"1507143574\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIMC\" target=\"_blank\">AIMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299375-altra-industrial-motion-takes-breather-shares-down-nearly-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Altra Industrial Motion takes breather; shares down nearly 4%</a></h4><ul><li>After a&nbsp;<font color='green'>60% Y/Y run higher,</font>&nbsp;Altra Industrial's (<a href='https://seekingalpha.com/symbol/AIMC' title='Altra Industrial Motion Corp.'>AIMC</a> <font color='red'>-3.8%</font>) is fully valued, says Baird's Michael Halloran.</li><li>Commodities remain volatile, he says, and PMIs at nosebleed levels suggest the next move in activity could be down.</li><li>Source: Bloomberg's Brad Olesen</li></ul><div class=\"tiny-share-widget\" data-id=\"3299375\" data-linked=\"Altra Industrial Motion takes breather; shares down nearly 4%\" data-tweet=\"$AIMC - Altra Industrial Motion takes breather; shares down nearly 4% https://seekingalpha.com/news/3299375-altra-industrial-motion-takes-breather-shares-down-nearly-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3299375-altra-industrial-motion-takes-breather-shares-down-nearly-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299373\" data-ts=\"1507143417\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299373-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DYSL' title='Dynasil Corporation of America'>DYSL</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/MTBC' title='Medical Transcription Billing'>MTBC</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/VNET' title='21Vianet Group'>VNET</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/SMSI' title='Smith Micro Software, Inc.'>SMSI</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SQNS' title='Sequans Communications'>SQNS</a> <font color='red'>-37%</font>. <a href='https://seekingalpha.com/symbol/SHOP' title='Shopify'>SHOP</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/IDT' title='IDT Corporation'>IDT</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/VJET' title='voxeljet AG'>VJET</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299373\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$DYSL $MTBC $I - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3299373-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3299373-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299370\" data-ts=\"1507142409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPRO\" target=\"_blank\">GPRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299370-gopro-shares-down-after-google-launch-event\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GoPro shares down after Google launch event</a></h4><ul><li>        GoPro (NASDAQ:<a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a>) shares are&nbsp;<font color='red'>down 4.28%</font>&nbsp;after the debut of Google Clips.</li><li>           The small Clips camera can clip onto a person or belongings and uses machine learning to determine what pictures or video the user would want to take &ndash; and will take those images on its own.&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3299331-google-pixel-2-launch-event-live-updates\" target=\"_blank\">Google Pixel 2 launch event: Live updates</a> (Oct. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299370\" data-linked=\"GoPro shares down after Google launch event\" data-tweet=\"$GPRO - GoPro shares down after Google launch event https://seekingalpha.com/news/3299370-gopro-shares-down-after-google-launch-event?source=tweet\" data-url=\"https://seekingalpha.com/news/3299370-gopro-shares-down-after-google-launch-event\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299367\" data-ts=\"1507141814\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WIN\" target=\"_blank\">WIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299367-windstreamplus-4_8-unitiplus-4_9-isda-panel-sees-no-bond-default\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Windstream +4.8, Uniti +4.9% as ISDA panel sees no bond default</a></h4><ul>   <li>Amid a few price hiccups today, Windstream Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/WIN' title='Windstream Holdings, Inc.'>WIN</a>) is <font color='green'>up 4.8%</font> after an ISDA panel has agreed unanimously that the company didn't trigger a CDS payout as part of its asset transfers tied to the spin-off of Communications Sales &amp; Leasing (now Uniti Group).</li>    <li>Uniti (NASDAQ:<a href='https://seekingalpha.com/symbol/UNIT' title='Uniti Group Inc.'>UNIT</a>), which depends on lease payments from Windstream for its network, is <font color='green'>up 4.9%</font>.</li>    <li>Shares in both Windstream and Uniti slipped last week after Aurelius Capital Management <a href=\"https://seekingalpha.com/news/3297620-windstream-minus-5_6-percent-noteholder-claims-default-spin-deal\" target=\"_blank\">claimed a default</a> based on what it said was a sale-leaseback around the spin-off.</li><li>The <a href=\"https://dc.isda.org/documents/2017/10/windstream-vote-oct-4.pdf\" target=\"_blank\">15-bank panel was unanimous</a> that there wasn't a CDS trigger in this case.</li>    <li>Also up are Windstream peers: <a href='https://seekingalpha.com/symbol/USM' title='United States Cellular Corporation'>USM</a> <font color='green'>+4.3%</font>; <a href='https://seekingalpha.com/symbol/CNSL' title='Consolidated Communications Holdings, Inc.'>CNSL</a> <font color='green'>+1.7%</font>; <a href='https://seekingalpha.com/symbol/CBB' title='Cincinnati Bell Inc.'>CBB</a> <font color='green'>+2.6%</font>; <a href='https://seekingalpha.com/symbol/HCOM' title='Hawaiian Telcom Holdco, Inc.'>HCOM</a> <font color='green'>+2.1%</font>; <a href='https://seekingalpha.com/symbol/SHEN' title='Shenandoah Telecommunications Co'>SHEN</a> <font color='green'>+1%</font>.</li>    <li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299367\" data-linked=\"Windstream +4.8, Uniti +4.9% as ISDA panel sees no bond default\" data-tweet=\"$WIN $WINMQ $UNIT - Windstream +4.8, Uniti +4.9% as ISDA panel sees no bond default https://seekingalpha.com/news/3299367-windstreamplus-4_8-unitiplus-4_9-isda-panel-sees-no-bond-default?source=tweet\" data-url=\"https://seekingalpha.com/news/3299367-windstreamplus-4_8-unitiplus-4_9-isda-panel-sees-no-bond-default\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>61&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299362\" data-ts=\"1507140253\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHOP\" target=\"_blank\">SHOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299362-baird-defends-shopify\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baird defends Shopify</a></h4><ul>     <li>Shopify (NYSE:<a href='https://seekingalpha.com/symbol/SHOP' title='Shopify'>SHOP</a>) is <a href=\"https://www.streetinsider.com/Analyst+Comments/Shopify+%28SHOP%29+Short+Report+Creates+Buying+Opportunity+-+Baird/13361040.html\" target=\"_blank\">defended</a> by Baird with shares&nbsp;<font color='red'>down 13% </font> after a short report attack from Citron this morning.</li><li>Analyst Colin Sebastian says the comparison by Citron to Herbalife isn't accurate and says a review of Shopify ads doesn't show many references to \"becoming a millionaire\" as alleged.</li><li>Shopify traded as low as $100.75 today vs. the 52-week range of $37.74 to $123.94.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299294-shopify-minus-8-percent-citron-warning\" target=\"_blank\">Shopify -8% after Citron warning</a> (Oct. 4)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299362\" data-linked=\"Baird defends Shopify\" data-tweet=\"$SHOP - Baird defends Shopify https://seekingalpha.com/news/3299362-baird-defends-shopify?source=tweet\" data-url=\"https://seekingalpha.com/news/3299362-baird-defends-shopify\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>67&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299361\" data-ts=\"1507140148\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAT\" target=\"_blank\">CAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299361-caterpillar-climbs-to-new-highs-following-upbeat-macquarie-comments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Caterpillar climbs to new highs following upbeat Macquarie comments</a></h4><ul>     <li>Caterpillar (<a href='https://seekingalpha.com/symbol/CAT' title='Caterpillar Inc.'>CAT</a> <font color='green'>+1%</font>) reaches new record highs after longtime CAT bear Sameer Rathod of Macquarie Research offers some <a href=\"http://www.marketwatch.com/story/caterpillars-stock-rallies-to-record-after-an-upbeat-comment-from-the-most-bearish-analyst-2017-10-04\" target=\"_blank\">upbeat comments</a> about used equipment pricing.</li>     <li>Rathod says his analysis of listings of used equipment suggests the pace of Y/Y price declines in September has slowed from the previous month, and that inventory continues to decline, which indicates the U.S. earth-moving markets are recovering.</li><li>Even with the upbeat outlook, Macquarie still has an Underperform rating on the stock and a $86 price target, the lowest among the 24 analysts followed by FactSet.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299361\" data-linked=\"Caterpillar climbs to new highs following upbeat Macquarie comments\" data-tweet=\"$CAT - Caterpillar climbs to new highs following upbeat Macquarie comments https://seekingalpha.com/news/3299361-caterpillar-climbs-to-new-highs-following-upbeat-macquarie-comments?source=tweet\" data-url=\"https://seekingalpha.com/news/3299361-caterpillar-climbs-to-new-highs-following-upbeat-macquarie-comments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299358\" data-ts=\"1507140057\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299358-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/LLEX' title='Lilis Energy, Inc.'>LLEX</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/AAU' title='Almaden Minerals Ltd'>AAU</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/JONE' title='Jones Energy, Inc.'>OTC:JONE</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CRK' title='Comstock Resources Inc.'>CRK</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/FTK' title='Flotek Industries, Inc.'>FTK</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/TTI' title='Tetra Technologies Inc.'>TTI</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/CIE' title='Cobalt International Energy, Inc.'>CIE</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299358\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$LLEX $AAU $JONE - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3299358-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3299358-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299355\" data-ts=\"1507137918\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TAK\" target=\"_blank\">TAK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299355-fda-oks-higher-dose-regimen-of-takedas-cancer-med-alunbrig-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs higher dose regimen of Takeda&#39;s cancer med Alunbrig; shares up 1%</a></h4><ul><li>The FDA approves Takeda Pharmaceutical's (TKPYY <font color='green'>+0.7%</font>) marketing application for a 180 mg tablet formulation of ALUNBRIG (brigatinib). The recommended dosing regimen is 90 mg once daily for the first seven days, then 180 mg once daily, if tolerated.</li><li>The FDA approved <a href=\"https://www.alunbrig.com/hcp?utm_source=google&amp;utm_medium=cpc&amp;utm_term=alunbrig&amp;utm_campaign=GS%2B-%2BNA%2B-%2BBR%2B-%2BBranded%2B-%2BPatient_GS%2B-%2BBrand%2BAlone_EX\" target=\"_blank\">ALUNBRIG </a>in a 30 mg tablet strength in April for the treatment of certain patients with ALK-positive lung cancer.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3261444-fda-oks-takedas-brigatinib-second-line-lung-cancer\" target=\"_blank\">FDA OKs Takeda's brigatinib for second-line lung cancer</a> (April 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299355\" data-linked=\"FDA OKs higher dose regimen of Takeda&#39;s cancer med Alunbrig; shares up 1%\" data-tweet=\"$TAK - FDA OKs higher dose regimen of Takeda&#39;s cancer med Alunbrig; shares up 1% https://seekingalpha.com/news/3299355-fda-oks-higher-dose-regimen-of-takedas-cancer-med-alunbrig-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3299355-fda-oks-higher-dose-regimen-of-takedas-cancer-med-alunbrig-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299351\" data-ts=\"1507136775\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299351-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/UNIT' title='Uniti Group Inc.'>UNIT</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='red'>-44%</font>. <a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings'>JP</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/MBI' title='MBIA Inc.'>MBI</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/AMBC' title='Ambac Financial'>AMBC</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299351\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$UNIT $RTNB $JP - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3299351-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3299351-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299347\" data-ts=\"1507136139\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299347-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MTBC' title='Medical Transcription Billing'>MTBC</a> <font color='green'>+34%</font>. <a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/CTMX' title='CytomX Therapeutics'>CTMX</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/FCEL' title='FuelCell Energy, Inc.'>FCEL</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/DYSL' title='Dynasil Corporation of America'>DYSL</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/IPDN' title='Professional Diversity Network'>IPDN</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/SMSI' title='Smith Micro Software, Inc.'>SMSI</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='red'>-45%</font>. <a href='https://seekingalpha.com/symbol/SQNS' title='Sequans Communications'>SQNS</a> <font color='red'>-39%</font>. <a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/SBBP' title='Strongbridge Biopharma'>SBBP</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/ODP' title='Office Depot Inc.'>ODP</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/MNTA' title='Momenta Pharmaceuticals, Inc.'>MNTA</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/OMNT' title='Ominto, Inc.'>OTCPK:OMNT</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/CHKE' title='Cherokee Inc.'>CHKE</a> <font color='red'>-13%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299347\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$MTBC $MNKD $KNDI - Midday Gainers / Losers https://seekingalpha.com/news/3299347-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3299347-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299344\" data-ts=\"1507135430\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAP\" target=\"_blank\">AAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299344-advance-auto-parts-falls-after-raymond-james-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Advance Auto Parts falls after Raymond James downgrade</a></h4><ul><li>Shares of Advance Auto Parts (NYSE:<a href='https://seekingalpha.com/symbol/AAP' title='Advance Auto Parts, Inc.'>AAP</a>) are&nbsp;<font color='red'>down 3.85%</font>&nbsp;after Raymond James <a href=\"https://www.benzinga.com/analyst-ratings/upgrades/17/10/10139028/benzingas-top-upgrades-downgrades-for-october-4-2017\" target=\"_blank\">downgrades</a> the retailer to Market Perform from Strong Buy.</li><li>Analyst Dan Wewer and team see increased risk to AAP's margins and warn that the company could lose its investment-grade credit rating.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299344\" data-linked=\"Advance Auto Parts falls after Raymond James downgrade\" data-tweet=\"$AAP - Advance Auto Parts falls after Raymond James downgrade https://seekingalpha.com/news/3299344-advance-auto-parts-falls-after-raymond-james-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3299344-advance-auto-parts-falls-after-raymond-james-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299334\" data-ts=\"1507133340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NCLH\" target=\"_blank\">NCLH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299334-cruise-lines-buoyed-rebounding-caribbean-demand\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cruise lines buoyed by rebounding Caribbean demand</a></h4><ul><li>It's been a rough six weeks for the cruise line players, but they're higher across the board today, with Barclays' Felicia Hendrix noting call volumes for Caribbean trips as rising and improving each day. She figures they'll be back to normal levels within two weeks.</li><li>Booking volumes and pricing are strong across all markets, with China looking slightly better in 2018 than 2017</li><li>Norwegian Cruise (<a href='https://seekingalpha.com/symbol/NCLH' title='Norwegian Cruise Line Holdings Ltd.'>NCLH</a> <font color='green'>+2.3%</font>), Carnival (<a href='https://seekingalpha.com/symbol/CCL' title='Carnival Corporation'>CCL</a> <font color='green'>+2%</font>), Royal Caribbean (<a href='https://seekingalpha.com/symbol/RCL' title='Royal Caribbean Cruises Ltd.'>RCL</a> <font color='green'>+2.7%</font>)</li><li>Source: Bloomberg's Naula Ndugga</li></ul><div class=\"tiny-share-widget\" data-id=\"3299334\" data-linked=\"Cruise lines buoyed by rebounding Caribbean demand\" data-tweet=\"$NCLH $NCLH $CCL - Cruise lines buoyed by rebounding Caribbean demand https://seekingalpha.com/news/3299334-cruise-lines-buoyed-rebounding-caribbean-demand?source=tweet\" data-url=\"https://seekingalpha.com/news/3299334-cruise-lines-buoyed-rebounding-caribbean-demand\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299332\" data-ts=\"1507132855\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299332-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/FORD' title='Forward Industries, Inc.'>FORD</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CLW' title='Clearwater Paper Corporation'>CLW</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/CLXT' title='Calyxt, Inc.'>CLXT</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299332\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$KNDI $SORL $FORD - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3299332-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3299332-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299329\" data-ts=\"1507132533\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEON\" target=\"_blank\">NEON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299329-neonode-signs-airbar-distribution-agreement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neonode signs AirBar distribution agreement</a></h4><ul><li>        Neonode (NASDAQ:<a href='https://seekingalpha.com/symbol/NEON' title='Neonode, Inc.'>NEON</a>) <a href=\"https://seekingalpha.com/pr/16959579-neonode-signs-new-airbar-distributor-agreement-new-age-synnex-north-america-evaluating\" target=\"_blank\">signs</a> an AirBar distribution agreement with retail channel New Age Synnex.</li><li>               The AirBar is now available as an accessory option on Dell Inspiron 3000 non-touch laptops.&nbsp;</li><li>                  &ldquo;AirBar will be given greater prominence with in-store promotions during the Halloween, Cyber Week, Black Friday, and Holiday buying seasons. The promotional and selling activities will be for AirBar as a stand-alone device and bundled with the leading PC OEMs notebooks,&rdquo; says AirBar SVP Remo Behdasht. &nbsp;   </li><li>               Neonode shares are&nbsp;<font color='green'>up 4.03%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3299329\" data-linked=\"Neonode signs AirBar distribution agreement\" data-tweet=\"$NEON - Neonode signs AirBar distribution agreement https://seekingalpha.com/news/3299329-neonode-signs-airbar-distribution-agreement?source=tweet\" data-url=\"https://seekingalpha.com/news/3299329-neonode-signs-airbar-distribution-agreement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299328\" data-ts=\"1507131828\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XSPA\" target=\"_blank\">XSPA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299328-xpresspa-opens-full-service-location-in-charlotte-airport\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XpresSpa opens full-service location in Charlotte airport</a></h4><ul>   <li>XpresSpa, part of FORM Holdings (<a href=\"http://seekingalpha.com/symbol/FH\" target=\"_blank\">FH</a> <font color='green'>+3%</font>), has opened its <a href=\"https://seekingalpha.com/pr/16959236-xpresspa-opens-first-full-service-spa-charlotte-douglas-international-airport\" target=\"_blank\">first full-service spa</a> in Charlotte Douglas International Airport.</li>    <li>That's its second presence at the airport, including a kiosk it had opened previously. It plans to open a second full-service location in the airport \"this calendar year\" in an adjacent concourse.</li>    <li>The airport is the nation's ninth-busiest, serving 45M passengers last year.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299328\" data-linked=\"XpresSpa opens full-service location in Charlotte airport\" data-tweet=\"$XSPA - XpresSpa opens full-service location in Charlotte airport https://seekingalpha.com/news/3299328-xpresspa-opens-full-service-location-in-charlotte-airport?source=tweet\" data-url=\"https://seekingalpha.com/news/3299328-xpresspa-opens-full-service-location-in-charlotte-airport\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299325\" data-ts=\"1507131812\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTBX\" target=\"_blank\">HTBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299325-heat-bio-aims-to-accelerate-development-of-two-pipeline-candidates-via-deal-selexis-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Heat Bio aims to accelerate development of two pipeline candidates via deal with Selexis; shares ahead 8%</a></h4><ul><li>Heat Biologics (<a href='https://seekingalpha.com/symbol/HTBX' title='Heat Biologics, Inc.'>HTBX</a> <font color='green'>+7.6%</font>) subsidiary Pelican Therapeutics inks an <a href=\"https://seekingalpha.com/pr/16959158-selexis-sa-pelican-therapeutics-sign-agreement-advance-pelican-s-immunotherapy-clinical\" target=\"_blank\">agreement</a> with Selexis SA leveraging its <a href=\"http://www.selexis.com/technology/gene-technology-and-procedures/\" target=\"_blank\">SUREtechnology </a>platform to rapidly develop research cell banks expressing two of Pelican's pipeline candidates: PTX-35 (website says <a href=\"http://www.pelicantherapeutics.com/products\" target=\"_blank\">PTX-25</a>), a humanized monoclonal antibody agonist of a tumor necrosis factor &#40;TNF&#41; receptor called TNFRSF25, and PTX-15, a human TL1A-Ig fusion protein. The company says both have the potential to improve clinical response when used with Heat's ImPACT therapeutic platform and other immunotherapy drugs.</li><li>PTX-35, Pelican's lead candidate, stimulates \"memory\" CD8+ cytotoxic T cells by binding to TNFRSF25, thereby enhancing the durability of responses to immunotherapies.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299325\" data-linked=\"Heat Bio aims to accelerate development of two pipeline candidates via deal with Selexis; shares ahead 8%\" data-tweet=\"$HTBX - Heat Bio aims to accelerate development of two pipeline candidates via deal with Selexis; shares ahead 8% https://seekingalpha.com/news/3299325-heat-bio-aims-to-accelerate-development-of-two-pipeline-candidates-via-deal-selexis-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3299325-heat-bio-aims-to-accelerate-development-of-two-pipeline-candidates-via-deal-selexis-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299327\" data-ts=\"1507131785\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/THR\" target=\"_blank\">THR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299327-thermonplus-14-on-c-258m-purchase-of-cci-thermal-technologies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Thermon +14% on C$258M purchase of CCI Thermal Technologies</a></h4><ul>     <li>Thermon Group (<a href='https://seekingalpha.com/symbol/THR' title='Thermon Group'>THR</a> <font color='green'>+14.6%</font>) surges after <a href=\"https://seekingalpha.com/pr/16959033-thermon-announces-strategic-acquisition-cci-thermal-technologies-inc-cad-258-million\" target=\"_blank\">agreeing to acquire</a> CCI Thermal Technologies, an Alberta-based producer of engineered heating and filtration solutions for industrial and hazardous area applications, for C$258M.</li><li>THR says the dealt diversifies its  product portfolio and end market exposure, and will provide a platform for future  growth and consolidation in an adjacent, fragmented $800M market.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299327\" data-linked=\"Thermon +14% on C$258M purchase of CCI Thermal Technologies\" data-tweet=\"$THR - Thermon +14% on C$258M purchase of CCI Thermal Technologies https://seekingalpha.com/news/3299327-thermonplus-14-on-c-258m-purchase-of-cci-thermal-technologies?source=tweet\" data-url=\"https://seekingalpha.com/news/3299327-thermonplus-14-on-c-258m-purchase-of-cci-thermal-technologies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299323\" data-ts=\"1507130969\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRO\" target=\"_blank\">MRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299323-marathon-oil-sees-q3-u-s-production-high-end-of-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marathon Oil sees Q3 U.S. production at high end of guidance</a></h4><ul>     <li>Marathon Oil (<a href='https://seekingalpha.com/symbol/MRO' title='Marathon Oil Corporation'>MRO</a> <font color='green'>+1.8%</font>) says it expects Q3 U.S. E&amp;P production available for sale to average toward the <a href=\"https://seekingalpha.com/pr/16958730-marathon-oil-provides-post-harvey-operational-update\" target=\"_blank\">high end of its guidance</a> of 230K-240K net boe/day.</li>     <li>MRO suspended operations and shut-in production across its entire Eagle Ford position in south&nbsp;Texas before Hurricane Harvey made landfall but its facilities sustained very minimal damage, and the company expects Q3 Eagle Ford production to average ~100K net boe/day, in-line with Q2 levels.</li><li>MRO says it still expects 2017 capex of $2.1B-$2.2B, with U.S. resource plays expected to exit the year with both oil and boe production 23%-27% higher than Q4 2016.</li>          </ul><div class=\"tiny-share-widget\" data-id=\"3299323\" data-linked=\"Marathon Oil sees Q3 U.S. production at high end of guidance\" data-tweet=\"$MRO - Marathon Oil sees Q3 U.S. production at high end of guidance https://seekingalpha.com/news/3299323-marathon-oil-sees-q3-u-s-production-high-end-of-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3299323-marathon-oil-sees-q3-u-s-production-high-end-of-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299322\" data-ts=\"1507130556\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EDAP\" target=\"_blank\">EDAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299322-fda-clears-edaps-ablatherm-fusion-shares-up-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA clears EDAP&#39;s Ablatherm-Fusion; shares up 9%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16959192-edap-announces-fda-clearance-ablatherm-fusion-device\" target=\"_blank\">grants 510(k) clearance</a> for EDAP TMS SA's (<a href='https://seekingalpha.com/symbol/EDAP' title='EDAP TMS S.A.'>EDAP</a> <font color='green'>+8.9%</font>) Ablatherm-Fusion device for the precise targeting and ablation of prostate tissue in patients with localized prostate cancer. The company says this next-generation product combines MRI, 3D biopsy maps and ultrasound images to precisely identify the specific prostate tissue to be ablated. Market launch will begin immediately.</li><li>Ablatherm used high-intensity focused ultrasound &#40;HIFU&#41; to ablate (remove/vaporize) tissue.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299322\" data-linked=\"FDA clears EDAP&#39;s Ablatherm-Fusion; shares up 9%\" data-tweet=\"$EDAP - FDA clears EDAP&#39;s Ablatherm-Fusion; shares up 9% https://seekingalpha.com/news/3299322-fda-clears-edaps-ablatherm-fusion-shares-up-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3299322-fda-clears-edaps-ablatherm-fusion-shares-up-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299318\" data-ts=\"1507130147\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQNS\" target=\"_blank\">SQNS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299318-sequans-plummets-36-on-lowered-q3-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sequans plummets 36% on lowered Q3 guidance</a></h4><ul><li>           Sequans (NYSE:<a href='https://seekingalpha.com/symbol/SQNS' title='Sequans Communications'>SQNS</a>) shares&nbsp;<font color='red'>plummet 35.62%</font>&nbsp;following yesterday&rsquo;s aftermarket <a href=\"https://seekingalpha.com/pr/16958815-sequans-updates-third-quarter-guidance\" target=\"_blank\">adjustment</a> of Q3 guidance. </li><li> Revenue is now expected between $11M and $11.2M, down from $15M to $17M, compared to the $15.93M consensus. </li><li>           Loss per share now between $0.06 and $0.07 compared to the previous loss estimate of $0.05 to $0.07. Consensus estimates put loss per share at $0.05. &nbsp; </li><li>        Sequans attributes the lower guidance to weaker broadband-related product sales in emerging markets, excess U.S. channel inventory, and a delayed project conclusion.</li><li>           The company expects the broadband weakness to continue through the rest of this year.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3299318\" data-linked=\"Sequans plummets 36% on lowered Q3 guidance\" data-tweet=\"$SQNS - Sequans plummets 36% on lowered Q3 guidance https://seekingalpha.com/news/3299318-sequans-plummets-36-on-lowered-q3-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3299318-sequans-plummets-36-on-lowered-q3-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299284\" data-ts=\"1507129238\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299284-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/CTMX' title='CytomX Therapeutics'>CTMX</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/SNSS' title='Sunesis Pharmaceuticals, Inc.'>SNSS</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/SBBP' title='Strongbridge Biopharma'>SBBP</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/MNTA' title='Momenta Pharmaceuticals, Inc.'>MNTA</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/KOOL' title='Cesca Therapeutics Inc'>KOOL</a> <font color='red'>-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299284\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$MYL $NLNK $CTMX - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3299284-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3299284-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299311\" data-ts=\"1507128946\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XOMA\" target=\"_blank\">XOMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299311-xoma-inks-three-out-licensing-deals-for-access-to-phage-display-libraries-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XOMA inks three out-licensing deals for access to phage display libraries; shares up 1%</a></h4><ul><li>Thinly traded micro cap XOMA (<a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a> <font color='green'>+0.6%</font>) is up on light volume in early trading on the heels of its <a href=\"https://seekingalpha.com/pr/16959467-xoma-announces-multiple-new-license-agreements-proprietary-phage-display-libraries\" target=\"_blank\">announcement </a>that it has inked three non-exclusive licenses with three different companies allowing them access to its phage display libraries for antibody discovery. The three licensees are: Tizona Therapeutics, Torch Biosciences and LakePharma.</li><li>Under the terms of the agreements, XOMA is eligible to receive development and regulatory milestones plus single-digit royalties on net sales.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299311\" data-linked=\"XOMA inks three out-licensing deals for access to phage display libraries; shares up 1%\" data-tweet=\"$XOMA - XOMA inks three out-licensing deals for access to phage display libraries; shares up 1% https://seekingalpha.com/news/3299311-xoma-inks-three-out-licensing-deals-for-access-to-phage-display-libraries-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3299311-xoma-inks-three-out-licensing-deals-for-access-to-phage-display-libraries-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299310\" data-ts=\"1507128933\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGR\" target=\"_blank\">RGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299310-gun-control-discussion-picks-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gun control discussion picks up</a></h4><ul>     <li>Gun stocks continue to see bouncy trading as lawmakers start to look at how the Las Vegas mass shooter obtained his weapons and modifications.</li>     <li>Some Republicans have indicated on the record a willingness to look at the issue after the facts are in from the tragedy in Las Vegas.</li>     <li>President Trump is in Las Vegas today, but isn't expected to address gun control. Trump has had a mixed record on gun control based on public comments, but campaigned as a strong supporter of the NRA. Former adviser Steve Bannon is <a href=\"https://www.axios.com/trump-wont-pivot-to-gun-control-probably-2492197581.html\" target=\"_blank\">confident</a> that Trump won't pivot on the issue. \"Impossible: will be the end of everything,\" he texted back to Axios on the question.</li>     <li>Related stocks:&nbsp;Sturm Ruger (NYSE:<a href='https://seekingalpha.com/symbol/RGR' title='Sturm, Ruger & Company Inc.'>RGR</a>), Vista Outdoor (NYSE:<a href='https://seekingalpha.com/symbol/VSTO' title='Vista Outdoor'>VSTO</a>), ShotSpotter (NASDAQ:<a href='https://seekingalpha.com/symbol/SSTI' title='ShotSpotter'>SSTI</a>), American Outdoor Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/AOBC' title='American Outdoor Brands Corporation'>AOBC</a>), Dick's Sporting Goods (NYSE:<a href='https://seekingalpha.com/symbol/DKS' title='Dick&#39;s Sporting Goods, Inc.'>DKS</a>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299310\" data-linked=\"Gun control discussion picks up\" data-tweet=\"$RGR $RGR $VSTO - Gun control discussion picks up https://seekingalpha.com/news/3299310-gun-control-discussion-picks-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3299310-gun-control-discussion-picks-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>60&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299309\" data-ts=\"1507128857\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AA\" target=\"_blank\">AA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299309-alcoaplus-2-positive-bofa-merrill-note-outweighs-gabelli-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alcoa +2% as positive BofA Merrill note outweighs Gabelli downgrade</a></h4><ul>     <li>Alcoa (<a href='https://seekingalpha.com/symbol/AA' title='Alcoa Corporation'>AA</a> <font color='green'>+1.9%</font>) rises to a new 52-week high following a <a href=\"https://www.streetinsider.com/Analyst+Comments/Alcoa+%28AA%29+PT+Raised+to+%2456+at+BofAMerrill+Lynch%2C+Positively+Revises+EPS+Estimates/13358593.html\" target=\"_blank\">positive analysis</a> from BofA&nbsp;Merrill Lynch, which raises its stock price target to $56 from $50 and maintains its Buy rating.</li>     <li>The firm says China's capacity cut for aluminum should support prices and benefit Alcoa, and raises its FY 2017 EPS estimate to $4.10 from $3.15 and its FY 2018 EPS estimate to $4.55 from $3.50.</li>     <li>BofA's upbeat take outweighs Gabelli's AA <a href=\"http://thefly.com/thestreet/realmoney/index.php/AAid2618361/AA-Alcoa-downgraded-to-Hold-from-Buy-at-Gabelli\" target=\"_blank\">downgrade</a> to Hold from Buy, citing valuation as recent price action in proxy Alumina Ltd. over-represents alumina fundamentals.</li>     <li>Gabelli also believes a merger with Rio Tinto's (<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color='green'>+0.7%</font>) aluminum becomes less likely until prices normalize.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299309\" data-linked=\"Alcoa +2% as positive BofA Merrill note outweighs Gabelli downgrade\" data-tweet=\"$AA $AA $RIO - Alcoa +2% as positive BofA Merrill note outweighs Gabelli downgrade https://seekingalpha.com/news/3299309-alcoaplus-2-positive-bofa-merrill-note-outweighs-gabelli-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3299309-alcoaplus-2-positive-bofa-merrill-note-outweighs-gabelli-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299307\" data-ts=\"1507128628\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PUBGY\" target=\"_blank\">PUBGY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299307-ad-agencies-moving-up-on-capgemini-hints-of-consolidation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ad agencies moving up on CapGemini hints of consolidation</a></h4><ul>   <li>Publicis Groupe (<a href='https://seekingalpha.com/symbol/PUBGY' title='Publicis Groupe S.A. ADR'>OTCQX:PUBGY</a>) is <font color='green'>up 3%</font> in U.S. trading on <a href=\"https://www.reuters.com/article/us-amazon-com-france/french-retailer-leclerc-approached-by-amazon-over-logistics-partnership-idUSKBN1C91SW?feedType=nl&amp;feedName=innovationNews&amp;utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=US%20Deals%20Today%202017-10-04&amp;utm_term=US%20Deals%20Today\" target=\"_blank\">hints of takeover talk</a> in the industry from software group CapGemini (<a href=\"http://seekingalpha.com/symbol/CGEMY\" target=\"_blank\">CGEMY</a> <font color='red'>-1%</font>).</li>    <li>CapGemini chief Paul Hermelin says his firm might have to get into the ad industry if rival Accenture (<a href=\"http://seekingalpha.com/symbol/ACN\" target=\"_blank\">ACN</a> <font color='green'>+0.4%</font>) makes a move there.</li>    <li>\"If Accenture bought a major global advertising company, the pressure put on us by the market and our shareholders would be big,\" Hermelin tells <i>Le Figaro.</i> \"In that situation, we would have to think of how to move into the advertising industry.\"</li>    <li>A move for one of the ad agency giants would follow similar consolidation discussions, with Bain Capital looks to buy Asatsu-DK and Vivendi acquiring Havas.</li>    <li>Rival ad giants up as well: WPPGY <font color='green'>+1.6%</font>; <a href='https://seekingalpha.com/symbol/OMC' title='Omnicom Group Inc.'>OMC</a> <font color='green'>+1.9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299307\" data-linked=\"Ad agencies moving up on CapGemini hints of consolidation\" data-tweet=\"$PUBGY $PUBGY $WPP - Ad agencies moving up on CapGemini hints of consolidation https://seekingalpha.com/news/3299307-ad-agencies-moving-up-on-capgemini-hints-of-consolidation?source=tweet\" data-url=\"https://seekingalpha.com/news/3299307-ad-agencies-moving-up-on-capgemini-hints-of-consolidation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299304\" data-ts=\"1507128373\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299304-cowen-bearish-on-teva-after-fda-nod-for-mylans-generic-copaxone\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen bearish on Teva after FDA nod for Mylan&#39;s generic Copaxone</a></h4><ul><li>Cowen's Ken Cacciatore says investors should avoid Teva Pharmaceutical Industries (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='red'>-14%</font>) citing a \"painful nightmare scenario\" on the heels of the FDA's OK of Mylan's (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='green'>+19.7%</font>) generic version of top seller Copaxone.</li><li>He has cut his price target to $18 from $30, although shares are currently exchanging hands at ~$16, adding that \"deep value\" investors may jump on board if shares dip to the $10 - 13 range.</li><li>Best-case scenario has TEVA maintaining ~$3.5B in cash flow next year.</li><li>Source: Bloomberg</li><li><strong>Update</strong>: FiercePharma <a href=\"http://www.fiercepharma.com/pharma/teva-scrambles-to-match-30-copaxone-discounts-from-mylan-s-knockoff-analyst\" target=\"_blank\">reports</a> that Mylan is offering discounts of 25 - 30% off Copaxone 40 mg.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299304\" data-linked=\"Cowen bearish on Teva after FDA nod for Mylan&#39;s generic Copaxone\" data-tweet=\"$TEVA $TEVA $MYL - Cowen bearish on Teva after FDA nod for Mylan&#39;s generic Copaxone https://seekingalpha.com/news/3299304-cowen-bearish-on-teva-after-fda-nod-for-mylans-generic-copaxone?source=tweet\" data-url=\"https://seekingalpha.com/news/3299304-cowen-bearish-on-teva-after-fda-nod-for-mylans-generic-copaxone\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299303\" data-ts=\"1507127852\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLM\" target=\"_blank\">SHLM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299303-buyout-talk-sends-schulman-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buyout talk sends A. Schulman higher</a></h4><ul> <li>Shares of A. Schulman (NASDAQ:<a href='https://seekingalpha.com/symbol/SHLM' title='A. Schulman, Inc.'>SHLM</a>) jump after The Wall Street Journal <a href=\"https://www.wsj.com/articles/plastics-company-a-schulman-weighs-sale-1507127449\" target=\"_blank\">reports</a> that the company is exploring a sale.</li> <li>Sources indicate that the sale process is in the early stages.</li> <li>A. Schulman is&nbsp;<font color='green'>up 4.74%</font>&nbsp;on strong volume and trades 26% higher than where it stood six months ago.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299303\" data-linked=\"Buyout talk sends A. Schulman higher\" data-tweet=\"$SHLM - Buyout talk sends A. Schulman higher https://seekingalpha.com/news/3299303-buyout-talk-sends-schulman-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3299303-buyout-talk-sends-schulman-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299302\" data-ts=\"1507127703\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMPH\" target=\"_blank\">KMPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299302-kempharm-in-licenses-tourette-adhd-candidate-from-genco-shares-up-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KemPharm in-licenses Tourette/ADHD candidate from Genco; shares up 7%</a></h4><ul><li>Thinly traded nano cap KemPharm (<a href='https://seekingalpha.com/symbol/KMPH' title='KemPharm'>KMPH</a> <font color='green'>+6.6%</font>) is up on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16959034-kempharm-genco-sciences-announce-technology-licensing-agreement-develop-prodrug-based-therapy\" target=\"_blank\">announcement </a>that it inked an agreement with Genco Sciences, LLC for exclusive rights to develop and commercialize its product candidate for the treatment of children with Tourette's syndrome who also suffer from attention deficit hyperactivity disorder &#40;ADHD&#41;.</li><li>KemPharm plans to leverage Genco's proprietary nanoparticulate amphetamine technology to develop a prodrug for the indication.</li><li>Under the terms of the contract, KemPharm will be responsible for financing and product development. Genco will be eligible to receive milestone payments and royalties. Specific financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299302\" data-linked=\"KemPharm in-licenses Tourette/ADHD candidate from Genco; shares up 7%\" data-tweet=\"$KMPH - KemPharm in-licenses Tourette/ADHD candidate from Genco; shares up 7% https://seekingalpha.com/news/3299302-kempharm-in-licenses-tourette-adhd-candidate-from-genco-shares-up-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3299302-kempharm-in-licenses-tourette-adhd-candidate-from-genco-shares-up-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299301\" data-ts=\"1507127445\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299301-crude-futures-pares-losses-post-inventory-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude futures pares losses post inventory data</a></h4><ul>     <li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories</a>: Crude <strong>-6.0M</strong> barrels vs. -0.8M consensus, -1.8M last week.</li><li>Gasoline <strong>+1.6M</strong> barrels vs. +1.1M consensus, +1.1M last week.</li><li>Distillates <strong>-2.6M </strong>barrels vs. -1.8M consensus, -0.8M last week.</li><li>Futures&nbsp;<font color='red'>-0.38%</font>&nbsp;to $50.23.</li><li>ETFs:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3299301\" data-linked=\"Crude futures pares losses post inventory data\" data-tweet=\"$USO $OIL $UCO - Crude futures pares losses post inventory data https://seekingalpha.com/news/3299301-crude-futures-pares-losses-post-inventory-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3299301-crude-futures-pares-losses-post-inventory-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>143&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299299\" data-ts=\"1507127037\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROAN\" target=\"_blank\">ROAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299299-linn-energy-to-sell-wyoming-properties-for-200m-ups-share-buyback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Linn Energy to sell Wyoming properties for $200M, ups share buyback</a></h4><ul>     <li>Linn Energy (LNGG <font color='green'>+2.7%</font>) is higher after <a href=\"https://seekingalpha.com/pr/16958955-linn-energy-announces-sale-washakie-properties-200-million-increases-share-repurchase\" target=\"_blank\">agreeing to sell</a> its interest in Wyoming properties to an undisclosed buyer for $200M, as the company's agreements to sell non-core assets now total more than $1.3B YTD.</li>     <li>Linn says the properties to be sold consist of 163K net acres in the Washakie field in Wyoming with Q2 net production of 66 Mcfe/day, proved reserves of 226B cfe and proved developed PV-10 of $102M.</li>     <li>Linn also adds $200M to its share repurchase program, which now totals $400M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299299\" data-linked=\"Linn Energy to sell Wyoming properties for $200M, ups share buyback\" data-tweet=\"$ROAN - Linn Energy to sell Wyoming properties for $200M, ups share buyback https://seekingalpha.com/news/3299299-linn-energy-to-sell-wyoming-properties-for-200m-ups-share-buyback?source=tweet\" data-url=\"https://seekingalpha.com/news/3299299-linn-energy-to-sell-wyoming-properties-for-200m-ups-share-buyback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299297\" data-ts=\"1507126845\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBBP\" target=\"_blank\">SBBP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299297-strongbridge-biopharma-prices-stock-offering-6_25-shares-down-19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Strongbridge Biopharma prices stock offering at $6.25; shares down 19%</a></h4><ul><li>Strongbridge Biopharma plc (<a href='https://seekingalpha.com/symbol/SBBP' title='Strongbridge Biopharma'>SBBP</a> <font color='red'>-19.3%</font>) <a href=\"https://seekingalpha.com/pr/16959474-strongbridge-biopharma-plc-announces-pricing-public-offering-ordinary-shares\" target=\"_blank\">prices </a>its public offering of 4M shares of common stock at $6.25 per share. Closing date is October 6.</li><li>Yesterday's close was $7.50.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299297\" data-linked=\"Strongbridge Biopharma prices stock offering at $6.25; shares down 19%\" data-tweet=\"$SBBP - Strongbridge Biopharma prices stock offering at $6.25; shares down 19% https://seekingalpha.com/news/3299297-strongbridge-biopharma-prices-stock-offering-6_25-shares-down-19?source=tweet\" data-url=\"https://seekingalpha.com/news/3299297-strongbridge-biopharma-prices-stock-offering-6_25-shares-down-19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299295\" data-ts=\"1507125876\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AYI\" target=\"_blank\">AYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299295-acuity-brandsminus-3-ceo-cautious-on-end-market-demand\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acuity Brands -3% as CEO cautious on end market demand</a></h4><ul>     <li>Acuity Brands (<a href='https://seekingalpha.com/symbol/AYI' title='Acuity Brands, Inc. &#40;Holding Company&#41;'>AYI</a> <font color='red'>-2.9%</font>) opens sharply lower after beating <a href=\"https://seekingalpha.com/news/3299251-acuity-brands-beats-0_12-misses-revenue\" target=\"_blank\">FQ4 earnings</a> estimates but missing on revenues, saying it is \"cautious regarding a meaningful rebound in our end-markets over the next few quarters.\"</li>     <li>CEO&nbsp;Vernon Nagel says labor shortages in the construction industry and uncertainty related to  infrastructure spending and federal tax and trade policies warrant caution, and growth rates for lighting and building management solutions in the North American market likely will only reach the low single digits for FY 2018; the segment accounts for 97% of AYI&rsquo;s revenue.</li><li>However, Nagel expects AYI to outperform the growth rate of the market, and he remains bullish on prospects for continued profitable growth.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299295\" data-linked=\"Acuity Brands -3% as CEO cautious on end market demand\" data-tweet=\"$AYI - Acuity Brands -3% as CEO cautious on end market demand https://seekingalpha.com/news/3299295-acuity-brandsminus-3-ceo-cautious-on-end-market-demand?source=tweet\" data-url=\"https://seekingalpha.com/news/3299295-acuity-brandsminus-3-ceo-cautious-on-end-market-demand\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299294\" data-ts=\"1507125832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHOP\" target=\"_blank\">SHOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299294-shopifyminus-8-after-citron-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shopify -8% after Citron warning</a></h4><ul> <li>Shopify (NYSE:<a href='https://seekingalpha.com/symbol/SHOP' title='Shopify'>SHOP</a>) is <font color='red'>down 7.81%</font> after Citron Research comes calling with <a href=\"http://www.citronresearch.com/citron-exposes-dark-side-spotify-ftc-will-take-notice/\" target=\"_blank\">video release</a>&nbsp;on the retailer that is decisively on the bearish side.</li> <li>Citroen Managing Editor Andrew Left says the FTC is going to take notice of the actions of Shopify.</li> <li>Volume on Shopify is already over 1M shares.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299294\" data-linked=\"Shopify -8% after Citron warning\" data-tweet=\"$SHOP - Shopify -8% after Citron warning https://seekingalpha.com/news/3299294-shopifyminus-8-after-citron-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3299294-shopifyminus-8-after-citron-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>178&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299286\" data-ts=\"1507125113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299286-teva-says-u-s-launch-of-mylans-generic-copaxone-40-mg-shave-0_25-off-q4-eps-patent-appeals\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva says U.S. launch of Mylan&#39;s generic Copaxone 40 mg could shave $0.25 off Q4 EPS, patent appeals unsettled</a></h4><ul><li>In a <a href=\"https://seekingalpha.com/pr/16959479-teva-comments-anticipated-risk-u-s-launch-generic-glatiramer-acetate-40mg-ml-launch-generic\" target=\"_blank\">statement</a>, Teva Pharmaceutical Industries (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='red'>-12.2%</font>) says Mylan's (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='green'>+18.2%</font>) U.S. launch of its generic version of MS med Copaxone (glatiramer acetate) 40 mg could trim at least $0.25 off Q4's per-share earnings.</li><li>The company says Mylan's launch should be considered \"at-risk\" because two appeals of earlier patent infringement rulings have yet to be adjudicated. One pertains to a December 2016 inter partes review that found all claims of three Copaxone patents to be unpatentable. The other involves a January 2017 district court decision that declared certain claims of four Copaxone patents invalid. The appeals have been fully briefed and oral arguments are next.</li><li>Teva also sued five would-be generic competitors, including Mylan, for infringement of a patent covering a manufacturing process for glatiramer acetate product.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299286\" data-linked=\"Teva says U.S. launch of Mylan&#39;s generic Copaxone 40 mg could shave $0.25 off Q4 EPS, patent appeals unsettled\" data-tweet=\"$TEVA $TEVA $MYL - Teva says U.S. launch of Mylan&#39;s generic Copaxone 40 mg could shave $0.25 off Q4 EPS, patent appeals unsettled https://seekingalpha.com/news/3299286-teva-says-u-s-launch-of-mylans-generic-copaxone-40-mg-shave-0_25-off-q4-eps-patent-appeals?source=tweet\" data-url=\"https://seekingalpha.com/news/3299286-teva-says-u-s-launch-of-mylans-generic-copaxone-40-mg-shave-0_25-off-q4-eps-patent-appeals\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299278\" data-ts=\"1507123701\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAMP\" target=\"_blank\">CAMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299278-calampminus-2-jpmorgan-cutting-to-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CalAmp -2% with JPMorgan cutting to Sell</a></h4><ul>   <li>CalAmp (NASDAQ:<a href='https://seekingalpha.com/symbol/CAMP' title='CalAmp Corp.'>CAMP</a>) is <font color='red'>off 2%</font> premarket as JPMorgan puts on its sell sign and trims its price target.</li>    <li>Valuation drove the downgrade from Neutral. The stock is <font color='green'>up 28%</font> over the past month and <font color='green'>up 63%</font> YTD.</li>    <li>The firm cut its price target to $22, implying 8.7% downside from yesterday's close of $24.09.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299278\" data-linked=\"CalAmp -2% with JPMorgan cutting to Sell\" data-tweet=\"$CAMP - CalAmp -2% with JPMorgan cutting to Sell https://seekingalpha.com/news/3299278-calampminus-2-jpmorgan-cutting-to-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3299278-calampminus-2-jpmorgan-cutting-to-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299277\" data-ts=\"1507123621\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIOT\" target=\"_blank\">RIOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299277-bioptix-gets-blockchain-shares-up-21\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bioptix gets into blockchain; shares up 21%</a></h4><ul><li>Harkening back to the late 1990s bubble when a company could see a big lift in its stock price by announcing the creation of a website, Bioptix (BIOP) is&nbsp;<font color='green'>up 21%</font>&nbsp;premarket after changing its name to Riot Blockchain. The company plans to change its stock symbol to \"RIOT.\"</li><li>Or should we say, \"up another 21%.\" BIOP has more than doubled over the past month.</li><li>Alongside the name change, the company announces a strategic investment in Coinsquare, a Canadian cryptocurrency exchange.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16959200-bioptix-changing-name-riot-blockchain-company-shifts-focus-strategic-investor-operator\" target=\"_blank\">Press Release</a></li><li>Related tickers: <a href='https://seekingalpha.com/symbol/BTCS' title='BTCS Inc.'>OTCQB:BTCS</a>, <a href='https://seekingalpha.com/symbol/BTSC' title='Bitcoin Services, Inc.'>OTCPK:BTSC</a>, <a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>, <a href='https://seekingalpha.com/symbol/GAHC' title='Global Arena Holding, Inc.'>OTCPK:GAHC</a>, <a href='https://seekingalpha.com/symbol/ARSC' title='American Security Resources Corp.'>OTC:ARSC</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3299277\" data-linked=\"Bioptix gets into blockchain; shares up 21%\" data-tweet=\"$RIOT $RIOT $BTCS - Bioptix gets into blockchain; shares up 21% https://seekingalpha.com/news/3299277-bioptix-gets-blockchain-shares-up-21?source=tweet\" data-url=\"https://seekingalpha.com/news/3299277-bioptix-gets-blockchain-shares-up-21\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>101&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299275\" data-ts=\"1507123481\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATNM\" target=\"_blank\">ATNM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299275-actinium-advancing-mid-stage-study-of-leukemia-med-actimab-shares-ahead-10-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Actinium advancing mid-stage study of leukemia med Actimab-A; shares ahead 10% premarket</a></h4><ul><li>Nano cap Actinium Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/ATNM' title='Actinium Pharmaceuticals, Inc.'>ATNM</a>) is up&nbsp;<font color='green'>10%</font>&nbsp;premarket on robust volume in response to its<a href=\"https://seekingalpha.com/pr/16959036-actinium-pharmaceuticals-provides-update-actimab-phase-2-clinical-trial-patients-acute\" target=\"_blank\"> continued advancement</a> of a Phase 2 clinical trial assessing Actimab-A in patients with acute myeloid leukemia &#40;AML&#41;.</li><li>Active trial sites now total 16. An interim analysis will be done by year-end with topline data available in H1 2018.</li><li><a href=\"http://www.actiniumpharma.com/product-pipeline/actimab-a\" target=\"_blank\">Actimab-A</a> is a targeted cancer therapy comprised of monoclonal antibody lintuzumab that delivers the cytotoxic isotope actinium-225 to AML cells.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299275\" data-linked=\"Actinium advancing mid-stage study of leukemia med Actimab-A; shares ahead 10% premarket\" data-tweet=\"$ATNM - Actinium advancing mid-stage study of leukemia med Actimab-A; shares ahead 10% premarket https://seekingalpha.com/news/3299275-actinium-advancing-mid-stage-study-of-leukemia-med-actimab-shares-ahead-10-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3299275-actinium-advancing-mid-stage-study-of-leukemia-med-actimab-shares-ahead-10-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299274\" data-ts=\"1507123456\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LW\" target=\"_blank\">LW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299274-post-earnings-pop-for-lamb-wesson\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Post-earnings pop for Lamb Wesson</a></h4><ul> <li>Lamb Wesson (NYSE:<a href='https://seekingalpha.com/symbol/LW' title='Lamb Weston Holdings, Inc.'>LW</a>) trades higher after topping earnings estimates with its FQ1 report.</li> <li>Volume increased 2% during the quarter.</li> <li>The company backs its prior revenue guidance for FY18 growth at a low to mid single digit rate and expects EBITDA of $740M to $760M. \"We expect the operating environment to remain generally favorable during fiscal 2018, with solid demand for frozen potato products globally and tight manufacturing capacity,\" says CEO Tom Werner.</li> <li>Shares of Lamb Wesson are <font color='green'>up 5.77%</font> premarket to $49.89.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299274\" data-linked=\"Post-earnings pop for Lamb Wesson\" data-tweet=\"$LW - Post-earnings pop for Lamb Wesson https://seekingalpha.com/news/3299274-post-earnings-pop-for-lamb-wesson?source=tweet\" data-url=\"https://seekingalpha.com/news/3299274-post-earnings-pop-for-lamb-wesson\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299271\" data-ts=\"1507123230\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VNET\" target=\"_blank\">VNET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299271-chinas-21vianet-groupplus-7_4-on-morgan-stanley-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China&#39;s 21Vianet Group +7.4% on Morgan Stanley upgrade</a></h4><ul>   <li>Data-center services firm 21Vianet Group (NASDAQ:<a href='https://seekingalpha.com/symbol/VNET' title='21Vianet Group'>VNET</a>) is <font color='green'>up 7.4%</font> premarket on an upgrade to Overweight at Morgan Stanley, which calls it the top pick in China Internet infrastructure.</li>    <li>Comparable revenue growth will flip from flat or declining to double-digit growth in 2018, says analyst Yang Liu, thanks to 21Vianet getting out of its unprofitable Managed Network Services businesses.</li>    <li>The company's EV/EBITDA looks good compared to peers in the U.S. and China, the firm says.</li>    <li>A raised price target of $9.50 (from $6.30) implies 63.5% upside in shares.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299271\" data-linked=\"China&#39;s 21Vianet Group +7.4% on Morgan Stanley upgrade\" data-tweet=\"$VNET - China&#39;s 21Vianet Group +7.4% on Morgan Stanley upgrade https://seekingalpha.com/news/3299271-chinas-21vianet-groupplus-7_4-on-morgan-stanley-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3299271-chinas-21vianet-groupplus-7_4-on-morgan-stanley-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299270\" data-ts=\"1507123204\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299270-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/CTMX' title='CytomX Therapeutics'>CTMX</a> <font color='green'>+32%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3299150-cytomx-teams-amgen-develop-egfr-targeting-antibodies-cancer\" target=\"_blank\">teaming</a> up with Amgen to develop EGFR-targeting antibodies for cancer.</li>     <li><a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a> <font color='green'>+27%</font>&nbsp;as edasalonexent <a href=\"https://seekingalpha.com/news/3299227-catabasis-pharmas-edasalonexent-shows-long-term-treatment-effect-mid-stage-dmd-study-shares\" target=\"_blank\">shows</a> long-term treatment effect in mid-stage DMD study.</li>     <li><a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+21%</font>&nbsp;as its&nbsp;lead candidate CAP-1002 <a href=\"https://seekingalpha.com/news/3299247-capricors-lead-candidate-capminus-1002-shows-positive-effect-heart-function-young-men\" target=\"_blank\">shows</a> positive effect on heart function in young men with advanced DMD.</li>     <li><a href='https://seekingalpha.com/symbol/EDAP' title='EDAP TMS S.A.'>EDAP</a> <font color='green'>+18%</font>&nbsp;on FDA <a href=\"https://seekingalpha.com/pr/16959192-edap-announces-fda-clearance-ablatherm-fusion-device\" target=\"_blank\">approval</a> of Ablatherm-Fusion device.</li>     <li><a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='green'>+16%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3299263-premarket-analyst-action-healthcare\" target=\"_blank\">positive</a> analyst action.</li>     <li><a href='https://seekingalpha.com/symbol/VKTX' title='Viking Therapeutics'>VKTX</a> <font color='green'>+13%</font>&nbsp;as VK0214 <a href=\"https://seekingalpha.com/news/3299255-viking-therapeutics-vk0214-shows-treatment-effect-proof-concept-study-shares-ahead-12-percent\" target=\"_blank\">shows</a> treatment effect in proof-of-concept study.</li>     <li><a href='https://seekingalpha.com/symbol/FOLD' title='Amicus Therapeutics, Inc.'>FOLD</a> <font color='green'>+13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3299239-amicus-therapeutics-announces-new-positive-data-atb200-at2221-pompe-disease-shares-ahead-16\" target=\"_blank\">announcement</a> of new positive data on ATB200/AT2221 in Pompe disease.</li>     <li>BIOP <font color='green'>+12%</font>&nbsp;on strategic <a href=\"https://seekingalpha.com/pr/16959200-bioptix-changing-name-riot-blockchain-company-shifts-focus-strategic-investor-operator\" target=\"_blank\">investment</a> in Coinsquare Ltd.</li>     <li><a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Ltd.'>GLBS</a> <font color='green'>+11%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+7%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='green'>+7%</font>&nbsp;on right offering <a href=\"https://seekingalpha.com/pr/16959278-dryships-inc-announces-results-rights-offering\" target=\"_blank\">announcement</a>.</li>     <li><a href='https://seekingalpha.com/symbol/FCEL' title='FuelCell Energy, Inc.'>FCEL</a> <font color='green'>+7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3299238-fuelcell-plus-6-percent-oppenheimer-starts-outperform-cash-flow-outlook\" target=\"_blank\">positive</a> analyst action.</li>     <li><a href='https://seekingalpha.com/symbol/TISA' title='Top Image Systems, Ltd.'>TISA</a> <font color='green'>+6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299270\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$CTMX $CATB $CAPR - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3299270-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3299270-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299269\" data-ts=\"1507123180\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299269-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='red'>-31%</font>.</li><li><a href='https://seekingalpha.com/symbol/MNTA' title='Momenta Pharmaceuticals, Inc.'>MNTA</a>&nbsp;<font color='red'>-23%</font>&nbsp;on FDA's <a href=\"https://seekingalpha.com/news/3299225-fda-ok-mylans-generic-copaxone-sinks-momenta-31-percent-premarket\" target=\"_blank\">approval</a> of Mylan's 40 mg version of Copaxone.</li><li><a href='https://seekingalpha.com/symbol/SBBP' title='Strongbridge Biopharma'>SBBP</a> <font color='red'>-17%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16958660-strongbridge-biopharma-plc-announces-proposed-public-offering-ordinary-shares\" target=\"_blank\">announcing</a> proposed public offering of ordinary shares.</li><li><a href='https://seekingalpha.com/symbol/ECYT' title='Endocyte, Inc.'>ECYT</a> <font color='red'>-15%</font>.</li><li><a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>&nbsp;<font color='red'>-12%</font>. on FDA's&nbsp;<a href=\"https://seekingalpha.com/news/3299218-fda-oks-mylans-generic-copaxone-shares-ahead-17-percent-premarket\" target=\"_blank\">approval</a>&nbsp;of Mylan's 40 mg version of Copaxone.</li><li><a href='https://seekingalpha.com/symbol/ODP' title='Office Depot Inc.'>ODP</a>&nbsp;<font color='red'>-10%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3299159-office-depot-buying-compucom-1b-shares-slump-11-percent\" target=\"_blank\">buying</a> Compucom for about $1B.</li><li><a href='https://seekingalpha.com/symbol/ANTH' title='Anthera Pharmaceuticals, Inc.'>OTC:ANTH</a> <font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3299152-rigel-pharma-launches-40m-stock-offering-shares-9-percent-hours\" target=\"_blank\">launching</a> $40M stock offering.</li><li><a href='https://seekingalpha.com/symbol/MBI' title='MBIA Inc.'>MBI</a>&nbsp;<font color='red'>-7%</font>&nbsp;on president Trump <a href=\"https://seekingalpha.com/news/3299259-monolines-lower-president-mulls-wiping-puerto-rico-debt\" target=\"_blank\">wiping</a> out Puerto Rico debt.</li><li>ETRM <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3299269\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$CLSN $MNTA $SBBP - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3299269-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3299269-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299267\" data-ts=\"1507122845\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OASM\" target=\"_blank\">OASM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299267-oasmia-pharma-finance-chief-departs-shares-down-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oasmia Pharma finance chief departs; shares down 6% premarket</a></h4><ul><li>Oasmia Pharmaceutical AB (NASDAQ:<a href='https://seekingalpha.com/symbol/OASM' title='Oasmia Pharmaceutical'>OASM</a>) <a href=\"http://oasmia.com/en/press-release/oasmia-pharmaceutical-ab-announces-resignation-chief-financial-officer/\" target=\"_blank\">announces </a>that CFO Fredrik Gynnerstedt has resigned by mutual agreement. EVP Anders Blom will take over on an interim basis.</li><li>Shares are off&nbsp;<font color='red'>6%</font>&nbsp;premarket albeit on only 300 shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299267\" data-linked=\"Oasmia Pharma finance chief departs; shares down 6% premarket\" data-tweet=\"$OASM - Oasmia Pharma finance chief departs; shares down 6% premarket https://seekingalpha.com/news/3299267-oasmia-pharma-finance-chief-departs-shares-down-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3299267-oasmia-pharma-finance-chief-departs-shares-down-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299264\" data-ts=\"1507122599\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGSE\" target=\"_blank\">RGSE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299264-rgs-energyplus-150-after-winning-license-deal-dow-chemical\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RGS Energy +150% after winning license deal with Dow Chemical</a></h4><ul>     <li>RGS Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/RGSE' title='RGS Energy, Inc.'>RGSE</a>) <font color='green'>+152.4%</font> premarket after announcing an exclusive domestic and international <a href=\"https://seekingalpha.com/pr/16959187-rgs-energy-dow-sign-exclusive-license-agreement-commercialize-powerhouse-solar-shingle\" target=\"_blank\">license agreement</a> with Dow Chemical (NYSE:<a href='https://seekingalpha.com/symbol/DWDP' title='DowDuPont Inc.'>DWDP</a>) for its Powerhouse solar shingles system.</li>     <li>RGS says it will lead all commercial activities for the product, including supply chain management, marketing, sales and installation.</li><li>RGS and Dow anticipate UL product certification during Q1 2018 and are taking pre-orders in advance of final written  certification.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299264\" data-linked=\"RGS Energy +150% after winning license deal with Dow Chemical\" data-tweet=\"$RGSE $RGSE $DD - RGS Energy +150% after winning license deal with Dow Chemical https://seekingalpha.com/news/3299264-rgs-energyplus-150-after-winning-license-deal-dow-chemical?source=tweet\" data-url=\"https://seekingalpha.com/news/3299264-rgs-energyplus-150-after-winning-license-deal-dow-chemical\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299263\" data-ts=\"1507122270\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299263-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Gilead Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>) resumed with Hold rating and $93 (12% upside) price target by Jefferies. Shares are up a fraction premarket.</li><li>Intercept Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a>) downgraded to Market Perform by JMP Securities. Shares down&nbsp;<font color='red'>2%</font>&nbsp;premarket on light volume.</li><li>Verex Imaging (NASDAQ:<a href='https://seekingalpha.com/symbol/VREX' title='Varex Imaging Corporation'>VREX</a>) downgraded to Underweight with a $33 (5% downside risk) price target by JPMorgan.</li><li>Mylan N.V. (NASDAQ:<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a>) price target raised to $45 (38% upside) from $42 by BTIG Research after FDA OK of generic Copaxone 40 mg. Shares are up&nbsp;<font color='green'>16%&nbsp;</font>premarket on robust volume.</li><li>RedHill Biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/RDHL' title='RedHill Biopharma Ltd.'>RDHL</a>) price target raised to $36 (283% upside) from $33 by H.C. Wainwright based on data from Phase 2 study of Bekinda in IBS-D. Shares up&nbsp;<font color='green'>3%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299263\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$GILD $GILD $ICPT - Premarket analyst action - healthcare https://seekingalpha.com/news/3299263-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3299263-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299261\" data-ts=\"1507122263\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299261-ubs-sees-u-s-momentum-for-netflix\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UBS sees U.S. momentum for Netflix</a></h4><ul> <li>Channel checks from UBS on Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) show continued strength across geographic markets for the streamer.</li> <li>The firm hikes its estimate on Q3 U.S. streaming additions to 850K from 750K. Netflix said in July that it anticipated 750K U.S. adds for the quarter.</li> <li>UBS raises its price target on Buy-rated Netflix to $225 from $190 to factor in the momentum.</li> <li>Sources: CNBC and Bloomberg</li> <li>Shares of Netflix are <font color='green'>up 1.21%</font> premarket to $181.36.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299261\" data-linked=\"UBS sees U.S. momentum for Netflix\" data-tweet=\"$NFLX - UBS sees U.S. momentum for Netflix https://seekingalpha.com/news/3299261-ubs-sees-u-s-momentum-for-netflix?source=tweet\" data-url=\"https://seekingalpha.com/news/3299261-ubs-sees-u-s-momentum-for-netflix\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299259\" data-ts=\"1507121861\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBI\" target=\"_blank\">MBI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299259-monolines-lower-president-mulls-wiping-out-puerto-rico-debt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Monolines lower as president mulls wiping out Puerto Rico debt</a></h4><ul><li>\"They owe a lot of money to your friends on Wall Street and we're going to have to wipe that out,\" <a href=\"https://www.cnbc.com/2017/10/03/trump-says-puerto-ricos-debt-will-have-to-be-wiped-out.html\" target=\"_blank\">the president told</a> Geraldo Rivera in an interview last night. \"You're going to say goodbye to that, I don't know if it's Goldman Sachs, but whoever it is you can wave goodbye to that.\"</li><li>Puerto Rico's benchmark 8% GO paper has tumbled to $0.34 on the dollar vs. $0.44 yesterday.</li><li>MBIA (NYSE:<a href='https://seekingalpha.com/symbol/MBI' title='MBIA Inc.'>MBI</a>)&nbsp;<font color='red'>-5.5%</font>, Assured Guaranty (NYSE:<a href='https://seekingalpha.com/symbol/AGO' title='Assured Guaranty Ltd.'>AGO</a>)&nbsp;<font color='red'>-4%</font>&nbsp;premarket. Ambac (NASDAQ:<a href='https://seekingalpha.com/symbol/AMBC' title='Ambac Financial'>AMBC</a>) is flat.</li><li>No details yet, but BTIG advises buying the dip.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299259\" data-linked=\"Monolines lower as president mulls wiping out Puerto Rico debt\" data-tweet=\"$MBI $MBI $AGO - Monolines lower as president mulls wiping out Puerto Rico debt https://seekingalpha.com/news/3299259-monolines-lower-president-mulls-wiping-out-puerto-rico-debt?source=tweet\" data-url=\"https://seekingalpha.com/news/3299259-monolines-lower-president-mulls-wiping-out-puerto-rico-debt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299255\" data-ts=\"1507121458\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VKTX\" target=\"_blank\">VKTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299255-viking-therapeutics-vk0214-shows-treatment-effect-in-proof-of-concept-study-shares-ahead-12\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viking Therapeutics&#39; VK0214 shows treatment effect in proof-of-concept study; shares ahead 12% premarket</a></h4><ul><li>Thinly traded nano cap Viking Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VKTX' title='Viking Therapeutics'>VKTX</a>) is up&nbsp;<font color='green'>12%&nbsp;</font>premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16959019-viking-therapeutics-announces-top-line-results-proof-concept-study-vk0214-vivo-model-x-linked\" target=\"_blank\">announcement </a>of positive results from a proof-of-concept study of VK0214 in a mouse model of X-linked&nbsp; adrenoleukodystrophy (X-ALD), an Orphan Drug indication in the U.S. The data will be presented at the 87th Annual Meeting of the American Thyroid Association in British Columbia, October 18 - 22.</li><li>Results showed treatment with VK0214 for 25 weeks produced significant effects on very long chain fatty acids (VLCFAs), including large reductions (45 - 82%) in plasma levels of a range of saturated fatty acids compared to controls.</li><li>Reductions in VLCFAs were also observed in the liver, brain and spinal cord.</li><li><a href=\"http://www.vikingtherapeutics.com/pipeline/vk0214/\" target=\"_blank\">VK0214&nbsp;</a>is an orally available thyroid receptor beta agonist that selectively regulates the expression of genes believed to be relevant to the presence of X-ALD.</li><li>X-ALD is a disease caused by the deterioration of fatty covering of nerves (myelin) which reduces the ability of the nerves to relay information to the brain. It also damages the outer layer of the adrenal glands which leads to the shortage of certain hormones (adrenocortical insufficiency). It occurs in ~1 in 17,000 births.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3195827-vikings-vk0214-shows-encouraging-preclinical-results-rare-inherited-lipid-disorder-shares-19\" target=\"_blank\">Viking's VK0214 shows encouraging preclinical results in rare inherited lipid disorder; shares up 19% premarket</a> (July 26, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299255\" data-linked=\"Viking Therapeutics&#39; VK0214 shows treatment effect in proof-of-concept study; shares ahead 12% premarket\" data-tweet=\"$VKTX - Viking Therapeutics&#39; VK0214 shows treatment effect in proof-of-concept study; shares ahead 12% premarket https://seekingalpha.com/news/3299255-viking-therapeutics-vk0214-shows-treatment-effect-in-proof-of-concept-study-shares-ahead-12?source=tweet\" data-url=\"https://seekingalpha.com/news/3299255-viking-therapeutics-vk0214-shows-treatment-effect-in-proof-of-concept-study-shares-ahead-12\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299247\" data-ts=\"1507120383\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAPR\" target=\"_blank\">CAPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299247-capricors-lead-candidate-capminus-1002-shows-positive-effect-on-heart-function-in-young-men\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capricor&#39;s lead candidate CAP-1002 shows positive effect on heart function in young men with advanced DMD; shares ahead 25% premarket</a></h4><ul><li>Capricor Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a>) is up&nbsp;<font color='green'>25%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16958978-capricor-therapeutics-presents-positive-six-month-results-duchenne-muscular-dystrophy-world\" target=\"_blank\">announcement </a>of positive data from its Phase 1/2 HOPE study assessing lead candidate CAP-1002 in young men with advanced Duchenne muscular dystrophy &#40;DMD&#41;. The results were presented today at the World Muscle Society Conference in France.</li><li>The open-label trial enrolled 25 DMD males aged 12 - 25, 17 who were wheelchair-dependent. All received a single dose of CAP-1002, administered into each of the three main coronary arteries to a total dose of 75M cells.</li><li>Cardiac function was assessed by MRI at month 6 and month 12. At month six, there was a statistically significant increase in mean inferior wall segments from baseline (p=0.02). Positive changes in anterior and lateral wall segments were also observed, but they were not statistically significant.</li><li>Positive effects were noted on muscle function as assessed by the Performance of the Upper Limb test &#40;PUL&#41;. At month 3, group results improved 33% from baseline compared to 10% for usual care (p=0.32).</li><li>The company plans to evaluate multiple doses of CAP-1002 in a larger study.</li><li><a href=\"http://capricor.com/product-pipeline/cap-1002/\" target=\"_blank\">CAP-1002</a>&nbsp;is an investigational allogeneic, off-the-shelf cardiac cell therapy derived from donor heart tissue and infused directly into the patient's coronary artery via a catheter.&nbsp;It is currently being evaluated for the treatment of heart disease associated with Duchenne muscular dystrophy and myocardial infarction (heart attack).</li></ul><div class=\"tiny-share-widget\" data-id=\"3299247\" data-linked=\"Capricor&#39;s lead candidate CAP-1002 shows positive effect on heart function in young men with advanced DMD; shares ahead 25% premarket\" data-tweet=\"$CAPR - Capricor&#39;s lead candidate CAP-1002 shows positive effect on heart function in young men with advanced DMD; shares ahead 25% premarket https://seekingalpha.com/news/3299247-capricors-lead-candidate-capminus-1002-shows-positive-effect-on-heart-function-in-young-men?source=tweet\" data-url=\"https://seekingalpha.com/news/3299247-capricors-lead-candidate-capminus-1002-shows-positive-effect-on-heart-function-in-young-men\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299253\" data-ts=\"1507120360\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JACK\" target=\"_blank\">JACK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299253-jack-in-box-on-watch-after-telsey-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jack in the Box on watch after Telsey upgrade</a></h4><ul> <li>Telsey lifts Jack in the Box (NASDAQ:<a href='https://seekingalpha.com/symbol/JACK' title='Jack In The Box Inc.'>JACK</a>) to an <a href=\"https://twitter.com/Briefingcom/status/915524608920510466\" target=\"_blank\">Outperform rating</a>.</li> <li>The investment firm hikes its price target to $118 to rep 18% upside potential.</li> <li>Shares of Jack in the Box are <font color='green'>up 1.79%</font> premarket to $101.12 vs. a 52-week trading range of $90.89 to $113.30.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299253\" data-linked=\"Jack in the Box on watch after Telsey upgrade\" data-tweet=\"$JACK - Jack in the Box on watch after Telsey upgrade https://seekingalpha.com/news/3299253-jack-in-box-on-watch-after-telsey-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3299253-jack-in-box-on-watch-after-telsey-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299248\" data-ts=\"1507119668\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLEX\" target=\"_blank\">LLEX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299248-lilis-energy-to-buy-4k-acres-in-delaware-basin-for-45m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lilis Energy to buy 4K acres in Delaware Basin for $45M</a></h4><ul>     <li>Lilis Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/LLEX' title='Lilis Energy, Inc.'>LLEX</a>)&nbsp;<font color='green'>+8.1%</font> premarket after <a href=\"https://seekingalpha.com/pr/16958954-lilis-energy-announces-delaware-basin-acquisition-wildhog-bwx-state-com-1h-ip24-rate\" target=\"_blank\">agreeing to acquire</a> ~4K net contiguous and overlapping acres in the Delaware Basin from an unnamed private seller for ~$45M.</li>     <li>LLEX says the acquisition will increase its acreage position in the Delaware to more than 15K net acres, exceeding its year-end 2017 acreage guidance; the deal adds more than 150 net potential locations to its inventory, bringing the total past 900.</li>     <li>LLEX also says it has one operated rig drilling in its Permian acreage with plans to add a second rig this month.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299248\" data-linked=\"Lilis Energy to buy 4K acres in Delaware Basin for $45M\" data-tweet=\"$LLEX - Lilis Energy to buy 4K acres in Delaware Basin for $45M https://seekingalpha.com/news/3299248-lilis-energy-to-buy-4k-acres-in-delaware-basin-for-45m?source=tweet\" data-url=\"https://seekingalpha.com/news/3299248-lilis-energy-to-buy-4k-acres-in-delaware-basin-for-45m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299245\" data-ts=\"1507119549\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBVX\" target=\"_blank\">MBVX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299245-mabvax-stockholders-approve-proposals-special-meeting-shares-off-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MabVax stockholders approve proposals at special meeting; shares off 3% premarket</a></h4><ul><li>MabVax Therapeutics (<a href='https://seekingalpha.com/symbol/MBVX' title='MABVAX THERAPEUTICS HLDGS'>OTCPK:MBVX</a>) <a href=\"https://seekingalpha.com/pr/16958809-mabvax-stockholders-approve-proposals-special-meeting-stockholders\" target=\"_blank\">announces</a> that its stockholders approved five out of six proposals at a Special Meeting of Stockholders re-convened on October 2.</li>                  <li>The resolution for Proposal One was not read at the Special Meeting, which has been adjourned to October 6 to allow additional time for MabVax stockholders to vote on the following proposal:</li><li>A reverse stock split of the Company's issued and outstanding common stock by a ratio of not less than one-for-two and not more than one-for-twenty at any time prior to September 28, 2018, with the exact ratio to be set at a whole number within this range as determined by the Board of Directors.</li> <li>The affirmative vote of over 50% of the issued and outstanding voting power is required for the approval of Proposal One.</li><li>The proposals 2 -5 were approved, all involved the issuance of additional shares of stock at the maximum discount of 30 or 20%.</li><li>Shares are down&nbsp;<font color='red'>3%</font>&nbsp;premarket on light volume. Yesterday's close was $0.650.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3299245\" data-linked=\"MabVax stockholders approve proposals at special meeting; shares off 3% premarket\" data-tweet=\"$MBVX $MBVXQ - MabVax stockholders approve proposals at special meeting; shares off 3% premarket https://seekingalpha.com/news/3299245-mabvax-stockholders-approve-proposals-special-meeting-shares-off-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3299245-mabvax-stockholders-approve-proposals-special-meeting-shares-off-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299241\" data-ts=\"1507119063\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MON\" target=\"_blank\">MON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299241-monsanto-beats-0_61-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Monsanto beats by $0.61, beats on revenue</a></h4><ul><li>Monsanto (NYSE:<a href='https://seekingalpha.com/symbol/MON' title='Monsanto Company'>MON</a>): Q4 EPS of $0.20 <font color='green'>beats by $0.61</font>.</li><li>Revenue of $2.69B (+5.1% Y/Y) <font color='green'>beats by $160M</font>.</li><li>Shares <font color='green'>+2.41%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16959184-monsanto-marks-record-sales-gross-profit-seeds-genomics-segment-fiscal-year-2017-fueled'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3299241\" data-linked=\"Monsanto beats by $0.61, beats on revenue\" data-tweet=\"$MON - Monsanto beats by $0.61, beats on revenue https://seekingalpha.com/news/3299241-monsanto-beats-0_61-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3299241-monsanto-beats-0_61-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299239\" data-ts=\"1507118718\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOLD\" target=\"_blank\">FOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299239-amicus-therapeutics-announces-new-positive-data-on-atb200-at2221-in-pompe-disease-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amicus Therapeutics announces new positive data on ATB200/AT2221 in Pompe disease; shares ahead 16% premarket</a></h4><ul><li>Amicus Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FOLD' title='Amicus Therapeutics, Inc.'>FOLD</a>) <a href=\"https://seekingalpha.com/pr/16958931-amicus-therapeutics-announces-additional-positive-data-pompe-disease-phase-1-2-study-world\" target=\"_blank\">announces</a> additional positive data from its Phase 1/2 clinical trial assessing ATB200/AT2221 in patients with Pompe disease, an inherited lysosomal storage disorder. The results were presented at the World Muscle Society Conference in France.</li><li>After six months of treatment, muscle function improved in 88.9% (n=16/18) of patients and was stable in the other two. Six-minute walk test distance improved at month 6 and was durable to month 9.</li><li>Pulmonary function either improved or was stable at months 6 and 9.</li><li><a href=\"http://amicusrx.com/pompe_disease.php\" target=\"_blank\">ATB200/AT2221</a>&nbsp;is a new treatment paradigm consisting of ATB200, a recombinant human enzyme called acid alpha-glucosidase with enhanced uptake characteristics, and AT2221, a pharmacological chaperone that improves activity and stability.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the data.</li><li>Shares are up&nbsp;<font color='green'>16%</font>&nbsp;premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3267279-amicus-atb200-at2221-shows-treatment-effect-early-stage-pompe-study-shares-ahead-7-percent\" target=\"_blank\">Amicus' ATB200/AT2221 shows treatment effect in early-stage Pompe study; shares ahead 7% premarket</a> (May 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299239\" data-linked=\"Amicus Therapeutics announces new positive data on ATB200/AT2221 in Pompe disease; shares ahead 16% premarket\" data-tweet=\"$FOLD - Amicus Therapeutics announces new positive data on ATB200/AT2221 in Pompe disease; shares ahead 16% premarket https://seekingalpha.com/news/3299239-amicus-therapeutics-announces-new-positive-data-on-atb200-at2221-in-pompe-disease-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3299239-amicus-therapeutics-announces-new-positive-data-on-atb200-at2221-in-pompe-disease-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299238\" data-ts=\"1507118712\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCEL\" target=\"_blank\">FCEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299238-fuelcellplus-6-oppenheimer-starts-outperform-on-cash-flow-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FuelCell +6% as Oppenheimer starts at Outperform on cash flow outlook</a></h4><ul>     <li>FuelCell Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/FCEL' title='FuelCell Energy, Inc.'>FCEL</a>) <font color='green'>+5.8%</font> premarket after Oppenheimer initiates coverage with an <a href=\"http://thefly.com/thestreet/realmoney/index.php/FCELid2617944/FCEL-FuelCell-initiated-with-an-Outperform-at-Oppenheimer\" target=\"_blank\">Outperform rating</a> and a $4 price target.</li><li>Oppy calls FCEL a \"clear leader\" in stationary fuel cell applications, and it believes the company can achieve positive operational cash flow in the next 12-18 months.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299238\" data-linked=\"FuelCell +6% as Oppenheimer starts at Outperform on cash flow outlook\" data-tweet=\"$FCEL - FuelCell +6% as Oppenheimer starts at Outperform on cash flow outlook https://seekingalpha.com/news/3299238-fuelcellplus-6-oppenheimer-starts-outperform-on-cash-flow-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3299238-fuelcellplus-6-oppenheimer-starts-outperform-on-cash-flow-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299227\" data-ts=\"1507117599\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CATB\" target=\"_blank\">CATB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299227-catabasis-pharmas-edasalonexent-shows-long-term-treatment-effect-in-mid-stage-dmd-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catabasis Pharma&#39;s edasalonexent shows long-term treatment effect in mid-stage DMD study; shares ahead 59% premarket</a></h4><ul><li>Catabasis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a>) is up&nbsp;<font color='green'>59%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16958896-catabasis-pharmaceuticals-reports-positive-results-open-label-extension-phase-2-movedmd-trial\" target=\"_blank\">announcement </a>of positive results from the open-label extension portion of its Phase 2 clinical trial, MoveDMD, assessing edasalonexent in boys with Duchenne muscular dystrophy &#40;DMD&#41;. The data were presented today the the World Muscle Society Conference in France.</li><li>Following 24 and 36 weeks of treatment with oral 100 mg/kg/day of edasalonexent, improvements were observed in the rate of decline compared to control. Muscle enzymes significantly decreased from baseline to week 12 and later time points (p&lt;0.05) and rate of change in lower leg muscle scans called MRI T2 also significantly beat control (p&lt;=0.05).</li><li>The company plans to advance edasalonexenet into Phase 3 development in H1 2018 with topline data expected in 2020.</li><li>Edasalonexent, a small molecule inhibitor of a protein called NF-kB, has Orphan Drug, Fast Track and Rare Pediatric Disease status in the U.S. and Orphan Drug status in Europe.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299227\" data-linked=\"Catabasis Pharma&#39;s edasalonexent shows long-term treatment effect in mid-stage DMD study; shares ahead 59% premarket\" data-tweet=\"$CATB - Catabasis Pharma&#39;s edasalonexent shows long-term treatment effect in mid-stage DMD study; shares ahead 59% premarket https://seekingalpha.com/news/3299227-catabasis-pharmas-edasalonexent-shows-long-term-treatment-effect-in-mid-stage-dmd-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3299227-catabasis-pharmas-edasalonexent-shows-long-term-treatment-effect-in-mid-stage-dmd-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299225\" data-ts=\"1507116345\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNTA\" target=\"_blank\">MNTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299225-fda-ok-of-mylans-generic-copaxone-sinks-momenta-down-31-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OK of Mylan&#39;s generic Copaxone sinks Momenta, down 31% premarket</a></h4><ul><li>The FDA's approval of Mylan's 40 mg version of Teva's Copaxone, the first approval at that dose, is weighing on Momenta Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MNTA' title='Momenta Pharmaceuticals, Inc.'>MNTA</a>) who has struggled to get its version on the U.S. market.</li><li>The FDA <a href=\"https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm443143.htm\" target=\"_blank\">approved </a>Momenta and partner Sandoz's 20 mg version in April, 2015, but the 40 mg dose represents the bulk of the business. The FDA also approved Mylan's 20 mg dose so Momenta will face this headwind.</li><li>MNTA is down&nbsp;<font color='red'>31%</font>&nbsp;premarket on modestly higher volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3245118-leerink-downgrades-momenta-uncertainty-generic-40-mg-glatiramer-acetate-price-target-cut-18\" target=\"_blank\">Leerink downgrades Momenta on uncertainty with generic 40 mg glatiramer acetate, price target cut to $18</a> (Feb. 22)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299218-fda-oks-mylans-generic-copaxone-shares-ahead-17-percent-premarket\" target=\"_blank\">FDA OKs Mylan's generic Copaxone; shares ahead 17% premarket</a> (Oct. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299225\" data-linked=\"FDA OK of Mylan&#39;s generic Copaxone sinks Momenta, down 31% premarket\" data-tweet=\"$MNTA - FDA OK of Mylan&#39;s generic Copaxone sinks Momenta, down 31% premarket https://seekingalpha.com/news/3299225-fda-ok-of-mylans-generic-copaxone-sinks-momenta-down-31-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3299225-fda-ok-of-mylans-generic-copaxone-sinks-momenta-down-31-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299218\" data-ts=\"1507115461\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYL\" target=\"_blank\">MYL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299218-fda-oks-mylans-generic-copaxone-shares-ahead-17-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Mylan&#39;s generic Copaxone; shares ahead 17% premarket</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16958822-mylan-announces-u-s-fda-approval-first-generic-copaxone-40-mg-ml-3-times-week-may-eligible\" target=\"_blank\">approves </a>Mylan N.V.'s (NASDAQ:<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a>) generic version of Teva Pharmaceutical Industries' (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) top seller Copaxone (glatiramer acetate injection) 40 mg/mL and 20 mg/mL for the treatment of relapsing forms of multiple sclerosis. Shipments will begin immediately.</li><li>Shares are up&nbsp;<font color='green'>17%</font>&nbsp;premarket. TEVA is down&nbsp;<font color='red'>11%</font>&nbsp;premarket. Both on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299218\" data-linked=\"FDA OKs Mylan&#39;s generic Copaxone; shares ahead 17% premarket\" data-tweet=\"$MYL $MYL $TEVA - FDA OKs Mylan&#39;s generic Copaxone; shares ahead 17% premarket https://seekingalpha.com/news/3299218-fda-oks-mylans-generic-copaxone-shares-ahead-17-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3299218-fda-oks-mylans-generic-copaxone-shares-ahead-17-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299215\" data-ts=\"1507115119\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLNK\" target=\"_blank\">NLNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299215-newlink-prices-stock-offering-10_25-shares-down-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NewLink prices stock offering at $10.25; shares down 6% premarket</a></h4><ul><li>NewLink Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a>) <a href=\"https://seekingalpha.com/pr/16958831-newlink-genetics-prices-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of 5M shares of common stock at $10.25 per share. Underwriters over-allotment is an additional 750K shares. Net proceeds will fund R&amp;D, working capital and general corporate purposes.</li><li>Yesterday's close was $10.91. Shares are down&nbsp;<font color='red'>6%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299215\" data-linked=\"NewLink prices stock offering at $10.25; shares down 6% premarket\" data-tweet=\"$NLNK - NewLink prices stock offering at $10.25; shares down 6% premarket https://seekingalpha.com/news/3299215-newlink-prices-stock-offering-10_25-shares-down-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3299215-newlink-prices-stock-offering-10_25-shares-down-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}